



Published in final edited form as:

Gastroenterology. 2013 January ; 144(1): 218–238. doi:10.1053/j.gastro.2012.10.028.

American Gastroenterological Association Technical Review on Constipation

ADIL E. BHARUCHA,

Division of Gastroenterology and Hepatology Mayo Clinic and Mayo Medical School Rochester, Minnesota

JOHN H. PEMBERTON, and

Division of Colon and Rectal Surgery Mayo Clinic and Mayo Medical School Rochester, Minnesota

G. RICHARD LOCKE III

Division of Gastroenterology and Hepatology Mayo Clinic and Mayo Medical School Rochester, Minnesota

Constipation is a very common symptom. Prompted by several advances since the last technical review 15 years ago,¹ this update will identify a rational, efficacious, and ideally cost-effective approach to patients with constipation. Toward those objectives, the epidemiology, clinical assessment, diagnostic testing, and management of constipation will be discussed, primarily from the perspective of a practicing gastroenterologist. Constipation in children and secondary constipation (eg, due to spinal cord injury) in adults will not be specifically addressed. This review was prepared by updating the previous technical review with material sourced from recent reviews on chronic constipation,^{2–4} supplemented by selected and focused literature searches of peer-reviewed, published studies. Although recommendations are graded based on US Preventive Services Task Force (USPSTF) ratings, formal cost-effectiveness analyses have not been performed. Comparisons of diagnostic approaches, with precise estimates of specificity and sensitivities, also have not been published. Indeed, in some instances, individual diagnostic techniques have not even been standardized.

Definition and Classification of Chronic Constipation

Constipation is a syndrome that is defined by bowel symptoms (difficult or infrequent passage of stool, hardness of stool, or a feeling of incomplete evacuation) that may occur either in isolation or secondary to another underlying disorder (eg, Parkinson's disease). Although many physicians regard constipation as synonymous with reduced stool frequency, others also consider straining to defecate, hard stools, and the inability to defecate at will as constipation.⁵ Hence, the Rome III symptom criteria for constipation incorporate several

© 2012 The American Gastroenterological Association. Published by Elsevier Inc. All rights reserved. ©2013 by the AGA Institute

Reprint requests Address requests for reprints to: Chair, Clinical Practice and Quality Management Committee, AGA National Office, 4930 Del Ray Avenue, Bethesda, Maryland 20814. drobin@gastro.org; telephone: (301) 272-1189..

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflicts of interest

The authors disclose the following: Mayo Clinic and A. E. Bharucha have a financial interest in a new technology related to anal manometry. G. R. Locke has been a consultant for Ironwood Pharmaceuticals, Movetis, Salix Pharmaceuticals, and ProStrakan, Inc.

bowel symptoms (Table 1); a diagnosis of defecatory disorders also requires abnormal anorectal test results.⁶ Constipation-predominant irritable bowel syndrome (IBS-C) is defined by abdominal discomfort that is temporally associated with 2 of the following 3 symptoms: relief of discomfort after defecation, hard stools, or less frequent stools. Although some patients with constipation also have abdominal discomfort, discomfort is not, in contrast to IBS-C, associated with these features.⁷ However, this distinction is of limited utility because patients are often uncertain about the temporal relationship between abdominal discomfort and these features. Moreover, compared with patients with constipation who do not have abdominal pain, patients with constipation who experience pain report poorer overall health and a greater impact of bowel symptoms on quality of life and more somatic symptoms regardless of whether the pain was or was not associated with characteristics of irritable bowel syndrome (IBS).⁸ Hence, the presence or absence of abdominal pain may be more useful than other associated features for characterizing phenotypes in chronic constipation.

The American Gastroenterological Association (AGA) and Rome III criteria both emphasize the need to identify defecatory disorders. However, in contrast to the Rome III criteria, the last AGA technical review and this update do not use the term “functional constipation” because a subset of patients with symptom criteria for functional constipation have slow colonic transit. Moreover, in several small studies, slow transit constipation (STC) was associated with a marked reduction in colonic intrinsic nerves and interstitial cells of Cajal,^{9,10} that is, it is not truly a functional disorder. Also, as detailed later, IBS-C is associated with various pathophysiological disturbances (eg, slow transit, abnormal colonic sensation). Hence, the AGA criteria rely on assessments of colonic transit and anorectal function to classify patients with constipation into one of 3 groups: normal transit constipation (NTC), STC, and pelvic floor dysfunction or defecatory disorders.

Prevalence and Risk Factors of Constipation

In October 2010, a MEDLINE literature review of the epidemiology of constipation identified 58 full-length articles on the prevalence of constipation in population-based samples of children and adults⁴; another study was not included therein.⁸ Subject to the caveats that definitions of constipation vary across studies and that some respondents in these questionnaire-based epidemiologic studies may have had an organic cause for constipation, the median prevalence of constipation was 16% (range, 0.7%–79%) in adults overall and 33.5% in adults aged 60 to 101 years. Most, but not all, studies suggest that the prevalence of constipation is higher in the nonwhite population than in the white population. The prevalence was higher in women (median female-to-male ratio of 1.5:1) and in institutionalized than community-living elderly residents.¹¹ Women are also more likely to use laxatives and seek health care for their constipation.

Risk Factors for Constipation

There is good agreement as to the risk factors for constipation. Lower socioeconomic status and lower parental education rates are associated with constipation,^{12–17} as are less self-reported physical activity,^{12,15,16,18,19} medications (Table 2), depression, physical and sexual abuse,²⁰ and stressful life events.^{16,17,21–23} The high prevalence of constipation in nursing home residents is only partly due to adverse drug effects.²⁴ Constipation was associated with low dietary fiber intake in some,¹⁸ but not other,²⁵ studies. However, these associations do not necessarily indicate causation. Although it is reasonable to try and modify these risk factors, doing so may not improve bowel function.

Economic Impact and Impact on Quality of Life

Although only a minority (eg, 22% in a US household survey) seek health care for constipation,²⁶ constipation consumes substantial health care resources because the prevalence is high. Among outpatient clinic visits, constipation is one of the 5 most common physician diagnoses for gastrointestinal disorders.²⁷ Between 1958 and 1986, an analysis of 4 different surveys (ie, the National Health Interview Survey, the National Hospital Discharge Survey, the National Ambulatory Medical Care Survey, and the Vital Statistics of the United States) estimated that there were approximately 2.5 million ambulatory care physician visits for constipation in the United States every year.¹⁷ More recently, data from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey suggest that ambulatory visits for constipation increased from 4 million per annum in 1993 to 1996 (ie, 0.46% of all ambulatory visits) to almost 8 million annually in 2001 to 2004 (ie, 0.72% of all ambulatory visits).²⁸ Between 2001 and 2004, the most recent epoch for which data are available, these visits were to adult primary care providers (33.4%), pediatricians (20.9%), and gastroenterologists (14.1%), which is equivalent to approximately 1.12 million patients referred to gastroenterologists for constipation per year. Women and adults aged 65 years and older were more likely to seek consultation than men and younger adults, respectively. To place the 8 million physician visits into perspective, 142,570 people developed colon or rectal cancer and 43,140 people developed pancreatic cancer in the United States in 2010.²⁹ These relative numbers highlight the problem of effectively identifying patients with colon cancer from among the multitude of patients with constipation. Moreover, they underscore the potential societal benefits of a rational approach to this symptom, such as when it does or does not warrant more extensive investigation.

Between 1958 and 1985, 85% of physician visits for constipation resulted in a prescription for over-the-counter laxatives or cathartics.¹⁷ Using different databases, this figure was 36% during 1993 to 1996 and 22% during 2001 to 2004.²⁸ Between 1993 and 1996 and between 2000 and 2004, use of bulking agents declined, use of osmotic laxatives increased, and use of stool softeners and stimulant laxatives did not change.²⁸ The annual direct medical costs for constipation were recently estimated to exceed \$230 million,³⁰ and the costs incurred by women with constipation were double that of women without constipation.³¹ The direct costs over 15 years were \$64,000 per person with constipation versus \$26,000 without. The challenge is estimating what costs must be due to constipation because this study included all costs incurred by people with constipation (ie, costs of any comorbidities were included). Population-based data are lacking as to the number of tests and procedures performed specifically for constipation in the United States. In a study of 51 patients seen in a surgical referral clinic (tertiary care), the average cost of the diagnostic evaluation was \$2752.³² The largest line item was the colonoscopy, which was responsible for more than one-third of the total expenditures. These investigators calculated the cost per patient who benefited from the evaluation to be \$11,697.³² The actual cost of performing colonoscopy is a challenge because this varies from location to location. Considering that 2.5 million people have constipation, the cost of performing colonoscopy is \$5 billion. Economic analyses have suggested that screening for colon cancer is cost-effective,³³ but formal economic analyses of the evaluation of constipation have not been performed. Because it is unlikely that patients with constipation are at lower risk for cancer, the performance of an anatomic evaluation of the colon in patients with constipation is thus likely to also be cost-effective. Constipation may, in fact, indicate a higher risk of colorectal malignancy^{33,34}; thus, exclusion of malignancy perhaps is the most cost-effective first step in approaching a patient with constipation. The challenge is to consider the patient's age. Young people with constipation are not likely to have colorectal cancer, but evaluation is cost-effective in those

older than 50 years. Of note, guidelines do not clearly state how often an evaluation should be performed in a person with symptoms; the guidelines are based on asymptomatic people.

To summarize these general aspects, constipation is common in the community, with prevalence estimates as high as 28%. A minority of those with constipation seek medical care, but this still accounts for 8 million annual physician visits in the United States. Most people see primary care providers and receive a prescription for laxatives, and they may undergo an anatomic evaluation of the colon. The role of the gastroenterologist is to assist in identifying selected patients with constipation who might benefit from additional testing or more specific treatments. By doing this, scarce health care resources may be used most efficiently.

A comprehensive literature search identified 10 studies, including 4 population-based studies, in which constipation was defined by the Rome criteria and quality of life was evaluated by a generic tool permitting comparisons with other conditions.³⁵ General health, mental health, and social functioning were impaired in people with constipation compared with healthy controls and more so in hospitalized patients than in the community. Among hospitalized patients, mental and physical subcomponent scores were comparable to those of unstable patients with Crohn's disease. Among people in the community, scores were comparable to those of patients with gastroesophageal reflux, hypertension, diabetes, and depression.³⁶

Pathophysiology

Virtually all studies on the pathophysiology of constipation emanate from tertiary centers rather than unselected people in the community.^{37–40} Although some patients (ie, up to 50% in some series) with defecatory disorders also have slow colonic transit,^{41–43} it is useful to consider mechanisms of STC and defecatory disorders separately. Understanding the pathophysiology of chronic constipation is useful for guiding therapy.

NTC and STC

In these guidelines, (isolated) STC refers to patients who do not have a defecatory disorder. Although slow colonic transit may reflect colonic motor dysfunction, it may also result from inadequate caloric intake.⁴⁴ Intraluminal assessments of colonic motility with manometry and a barostat reveal colonic motor dysfunction in some patients with STC.^{43,45,46} Manometric disturbances include fewer high-amplitude propagated contractions and reduced phasic contractile responses to a meal and/or to pharmacologic stimuli (eg, bisacodyl or neostigmine).^{45,46} However, because healthy subjects have 1 to 15 high-amplitude propagated contractions daily, only patients who have no high-amplitude propagated contractions over a 24-hour period have a true abnormality.⁴⁵ Increased nonpropagated or retrogradely propagated sigmoid or rectal phasic pressure activity, which may impede colonic flow, has also been described.⁴⁶ High-resolution colonic manometry suggests that there is less spatial overlap between adjacent propagated sequences.⁴⁶ Colonic inertia refers to patients with STC who also have markedly reduced or absent responses to a meal and to a pharmacologic stimulus (eg, bisacodyl or neostigmine).^{43,47} These colonic motor dysfunctions may be explained by a marked reduction in colonic intrinsic nerves and interstitial cells of Cajal,^{9,10} and this should prompt consideration of colonic resection in medically refractory patients who do not have pelvic floor dysfunction, as discussed later.

Barostat measurements revealed reduced fasting and/or postprandial colonic tone and/or compliance in 40% of patients with NTC, 47% with STC, 53% with defecatory disorders and normal transit, and 42% with defecatory disorders and slow transit.⁴³ In another study, 43% of patients with STC had normal fasting colonic motility and motor responses to a meal

and bisacodyl.⁴⁸ Together, these observations suggest that normal and slow colonic transit are imperfect surrogate markers for normal and abnormal colonic motor function, respectively. Although NTC has been mistakenly regarded as synonymous with IBS-C, 23% of patients with constipation or IBS-C had delayed colonic transit.⁴⁹ Hence, the relationship between colonic transit and motor functions needs to be clarified.

Sensory disturbances in chronic constipation depend on the rate of distention; findings include increased and reduced rectal sensation during rapid and slow distention, respectively.⁴⁰ Increased rectal sensitivity is associated with abdominal pain and bloating, suggestive of IBS,^{50,51} whereas slow colonic transit is associated with infrequent stools in some,⁵² but not all,⁵³ studies.

Defecatory Disorders

Defecatory disorders are primarily characterized by impaired rectal evacuation, with normal or delayed colonic transit.⁶ Conceptually, incomplete rectal evacuation may result from inadequate rectal propulsive forces and/or increased resistance to evacuation; the latter may result from high anal resting pressure (“anismus”), incomplete relaxation,⁵⁴ or paradoxical contraction of the pelvic floor and external anal sphincters (“dyssynergia”).⁴² However, these disturbances and other pseudonyms (eg, outlet obstruction, obstructed defecation) refer to the same disorder. These patterns are not associated with specific clinical features or the response to pelvic floor retraining.⁵⁵ Other disturbances in defecatory disorders include rectal hyposensitivity,⁵⁶ delayed colonic transit,^{43,57} and structural disturbances (eg, excessive perineal descent and rectoceles),^{58,59} Excessive straining may weaken the pelvic floor, causing excessive perineal descent, rectal intussusception, solitary rectal ulcer syndrome, and a pudendal neuropathy; pudendal neuropathy may weaken the anal sphincters, predisposing to fecal incontinence.^{58,60–62}

Several factors limit a precise understanding of the relationship between anorectal sensorimotor dysfunctions and symptoms of disordered defecation. First, even asymptomatic people and some patients with symptoms (eg, rectal pain) other than difficult defecation have dyssynergia, which undermines the significance of this finding.^{63,64} Perhaps this reflects the challenges of simulating defecation during anorectal testing. Patients may be restricted by feelings of inadequate privacy, and these voluntary components will, of necessity, vary among patients and even for the same person at different times. Second, these disturbances (eg, dyssynergia, rectoceles) may overlap, limiting an assessment of the contribution of individual disturbances. Third, some features (eg, rectal hyposensitivity and delayed colonic transit) may be consequences rather than causes of obstructed defecation because they may improve after successful biofeedback therapy.⁵⁷ Fourth, the findings of different tests (eg, anal manometry, defecography) may not concur and there is no gold standard for the diagnosis. Lastly, other factors, particularly stool form, likely influence expression of symptoms in pelvic floor dysfunction.

The etiology of defecatory disorders is unclear. Disordered defecation may be conceptualized as maladaptive learning of sphincter contraction, perhaps initiated by avoidance of pain or trauma⁶⁵ or even neglecting the call to defecate. Symptoms may date to childhood; indeed, one-third of children with childhood constipation continue to have severe symptoms beyond puberty.⁶⁶ Although obstetric trauma can damage the anal sphincter and pelvic floor, there is no evidence for an association between obstetric trauma and defecatory disorders.⁶⁷

Some people have both slow transit and a defecatory disorder. In these patients, the defecatory disorder cannot be identified by the pattern of delayed colonic transit (eg, regional left-sided vs overall delay).⁶⁸ Delayed colonic transit in defecatory disorders may

be attributable to physical obstruction to passage of contents by stool, rectocolonic inhibitory reflexes initiated by rectal distention from retained stool,⁶⁹ or colonic motor dysfunction, which is unrelated to defecatory disorders.⁴⁶

Clinical Evaluation

The clinical assessment must, in particular, elicit specific symptoms of constipation, clarify which symptoms are distressing, and inquire about medications that can cause (Table 2) or are used to treat constipation. Alarm symptoms include a sudden change in bowel habits after the age of 50 years, blood in stools, anemia, weight loss, and a family history of colon cancer. The timing of symptom onset, particularly relative to potential risk factors (eg, onset during childhood, use of prescription and over-the-counter medications, inadequate dietary calorie and fiber intake, obstetric events, and a history of abuse), should be clarified. As discussed previously, it is essential to characterize bowel habits and elucidate the specific symptoms of chronic constipation. Is the “call to stool” postprandial, initiated by abdominal discomfort and/or by a rectal sensation? Is the call always answered? What maneuvers (eg, straining to begin and/or to end defecation) are used to defecate? Although some symptoms (ie, anal digitation, a sense of anal blockage during defecation, or a sense of incomplete evacuation after defecation) suggest disordered defecation,⁷⁰ the evaluation of these symptoms by a questionnaire is not particularly useful for discriminating patients with constipation who have a normal versus an abnormal rectal balloon expulsion test result.⁷¹ Pictorial representations of stool form (eg, by the Bristol Stool Form Scale) and bowel diaries are efficient and reliable methods to characterize bowel habits and are better predictors of colonic transit than self-reported stool frequency.^{72,73} Moreover, self-reported stool frequency is unreliable.⁷⁴ Stool form also influences the ease of defecation.⁷⁵ For example, among women with constipation in the community, straining to begin defecation is more frequent (ie, approximately 40% vs approximately 20%) for hard stools than normal stools.⁷⁵ When evacuatory deficits are pronounced, even soft stools and enema fluid may be difficult to pass. After a complete purge, it will take several days for residue to accumulate such that a normal fecal mass will be formed. Hence, it is not uncommon for patients to skip a bowel movement for a few days after a bout of diarrhea. Use of laxatives in patients with constipation can also predispose to alternating constipation and diarrhea, which is common in IBS.⁷⁶ In a population study, 7% reported use of laxatives.^{77,78}

In addition to bowel disturbances, many patients, particularly those with IBS, have abdominal symptoms (eg, abdominal bloating, distention, or discomfort), nongastroenterological symptoms (eg, fatigue, malaise, fibromyalgia), or psychosocial distress. Many patients rank abdominal bloating, which may be associated with abdominal distention, as their most bothersome symptom.⁷⁹

The clinical assessment should consider diseases to which constipation is secondary (Table 3). A meticulous perineal and rectal examination is very useful for identifying defecatory disorders. Digital rectal examination can gauge anal resting tone. Pelvic contraction is normally accompanied by increased anal tone and a puborectalis “lift” (ie, anterosuperior motion toward the umbilicus); when patients are instructed to “expel the examining finger,” both muscles should relax with perineal descent, which is normally 2 to 4 cm.^{80,81} Patients with defecatory disorders may have high anal resting tone, as evidenced by increased resistance to insertion of the examining finger into the anal canal, and/or impaired relaxation or paradoxical contraction of the sphincter complex with reduced perineal descent during simulated evacuation. Other possible findings include stool in the rectal vault, fecal soiling on the perianal skin, a rectocele, or puborectalis tenderness. Among 209 patients (191 men) with chronic constipation, a digital rectal examination performed by a skilled clinician was 75% sensitive and 87% specific for diagnosing dyssynergia as predicted by manometry but

only 80% sensitive and 56% specific for predicting an abnormal rectal balloon expulsion test result, which is more useful for diagnosing defecatory disorders.⁸¹ The utility of a digital rectal examination is likely lower for less skilled examiners.

After obtaining a history and conducting a physical examination, physiological testing should be performed in patients with chronic constipation refractory to dietary fiber supplementation and/or over-the-counter laxatives. When the clinical index of suspicion for disordered defecation is high, anorectal testing may be considered sooner, perhaps even before a trial of fiber and over-the-counter laxatives. In addition, a complete blood cell count should be performed. Although fasting serum glucose, sensitive thyroid-stimulating hormone, and calcium levels are often measured, the diagnostic utility and cost-effectiveness of these tests have not been rigorously evaluated and are probably very low.⁸² Testing for colon cancer with imaging or endoscopy should be considered for all patients with alarm clinical features (eg, blood in stool, unexplained anemia, weight loss > 10 lb, abdominal or rectal mass), for all patients with constipation refractory to medical management, and for patients aged 50 years or older who have not undergone an age-appropriate colon cancer screening procedure after onset of constipation; this age specification is lower in some patients with a family history of colon cancer. Testing should also be considered in patients with an abrupt change in bowel habits without an obvious cause, recognizing the limitations of defining an abrupt change. Because the prevalence of colonic neoplastic lesions at colonoscopy is comparable in patients with versus without chronic constipation, routine colonoscopy is not warranted for most patients with constipation.⁸³

Patients are usually referred for specialty consultation because their symptoms have not responded to fiber supplements and/or over-the-counter laxatives. Given the variability of patient recall, gastroenterologists should consider evaluating symptoms with a bowel diary. Most secondary causes of constipation (Table 3) will be evident after obtaining a history and performing a physical examination. Although celiac disease is not associated with constipation in population-based studies, some patients with celiac disease report constipation at diagnosis and more so after treatment.^{84,85} Further laboratory and imaging studies may need to be selectively completed or repeated.

Defecatory disorders, which are by far the most common cause of medically refractory chronic constipation,⁸⁶ can often be recognized by a careful clinical assessment and substantiated by anorectal test results. In general, IBS-C is characterized predominantly by abdominal pain, bloating, or feelings of incomplete evacuation in addition to bowel disturbances. Thereafter, assessments of colonic transit, as well as intraluminal assessment of colonic motor activity in selected patients, are useful for identifying when constipation is caused by colonic motor dysfunction.⁷

Diagnostic Tests

Algorithm 1 in the medical position statement summarizes a preferred approach to diagnostic testing in patients with chronic constipation who have not responded to a high-fiber diet and/or over-the-counter laxatives after organic disorders have been excluded. Anorectal testing with manometry and a rectal balloon expulsion test are at the top of the pyramid and may be considered even before trying laxatives in patients with symptoms that are highly suggestive of pelvic floor dysfunction. In contrast to the previous medical position statement, assessment of colonic transit is not recommended in the early assessment for 2 reasons. First, because up to 50% of patients with defecatory disorders have slow colonic transit, slow transit does not circumvent anorectal testing or exclude the presence of defecatory disorders. Defecatory disorders are treated with pelvic floor retraining regardless

of colonic transit. Second, initial therapies (ie, laxatives) for NTC and STC are similar. If necessary, colonic transit and other tests follow.

Diagnostic approaches are compounded by the inherent limitations of anorectal testing, which have been discussed previously. Thus, the tests should be in a setting as private as possible to reduce embarrassment and facilitate cooperation, but ideal conditions are rarely possible. Indeed, these test results may be abnormal even in a small proportion of asymptomatic people. Moreover, false-positive and false-negative test results do occur and there is no single criterion standard diagnostic test for diagnosing defecatory disorders. Hence, test results need to be interpreted in the overall clinical context rather than in isolation. The studies referred to in the algorithm are listed in order of simplicity, cost, and general use.

Rectal Balloon Expulsion Test

This simple procedure, first described by Preston and Lennard-Jones,⁵⁴ evaluates a patient's ability to evacuate a water-filled balloon. It can be performed in isolation or in conjunction with anorectal manometry. The preferred approach is to quantify the time required to expel a rectal balloon in the seated position; depending on the technique, recommended normal values range from less than 1 minute to up to 5 minutes.^{87,88} Alternatively, the magnitude of additional passive forces needed to expel the balloon in the lateral decubitus position can be measured if spontaneous evacuation is not possible.⁸⁹ Depending on the technique, patients with pelvic floor dysfunction require more time or more external traction to expel the balloon. In a study of 106 patients with constipation and 24 patients with defecatory disorders diagnosed by defecography, rectal balloon expulsion was 87.5% sensitive and 89% specific with positive and negative predictive values of 64% and 97% for diagnosing defecatory disorders, respectively.⁹⁰ This uncontrolled study excluded patients with secondary (eg, medication-induced) chronic constipation. Although defecatory disorders were identified by a deviation in defecographic findings from the anticipated normal appearance, some asymptomatic subjects have abnormal pelvic floor motion by barium defecography.⁹¹ Contrary to the approach in most clinical laboratories, the rectal balloon was inflated by a variable volume, averaging 183 mL, until patients experienced the desire to defecate rather than a fixed volume. Variable distention may compensate for reduced rectal sensation, which is associated with defecatory disorders.⁵⁶ However, these 2 techniques (ie, fixed vs variable balloon inflation) have not been compared.

Anorectal Manometry

This procedure has greatest value in (1) excluding Hirschsprung's disease by the presence of a normal rectoanal inhibitory reflex and (2) supporting a clinical impression of defecatory disorders as evidenced by high anal resting pressures, typically 90 mm Hg (anismus), with relatively little voluntary augmentation, suggestive of a nonrelaxing pelvic floor/sphincter dysfunction⁹² or an abnormal (ie, lower) rectoanal pressure gradient during simulated evacuation. The precise utility of a low rectoanal pressure gradient to diagnose defecatory disorders is unclear because there is considerable overlap in values for this parameter between asymptomatic subjects and patients with defecatory disorders.^{42,71,88} Therefore, the rectoanal gradient should not be used in isolation to diagnose defecatory disorders. The methods for anorectal manometry are not standardized and are reviewed extensively elsewhere.⁹³ Hence, data from center to center cannot be generalized. Both traditional approaches (ie, water-perfused or solid-state manometric sensors) are of comparable utility and generally correlated with high-resolution manometry.⁹⁴ In contrast to traditional sensors, high-resolution manometric catheters have several evenly distributed sensors situated along the catheter that straddle the entire anal canal, allowing pressures to be assessed without a pull-through maneuver.

Barium, Scintigraphic, and Magnetic Resonance Defecography

Defecography is particularly useful when the results of anorectal testing are inconsistent with the clinical impression and/or to identify anatomic abnormalities.^{6,91,93,95} The most relevant findings in defecatory disorders include inadequate (ie, “spastic” disorder) or excessive (“flaccid perineum,” “descending perineum syndrome”) widening of the anorectal angle and/or perineal descent during defecation. Excessive straining, internal intussusception, solitary rectal ulcers, rectoceles, and rectal prolapse may also be observed.⁹⁶ If the vagina and small intestine are opacified, enteroceles as well as bladder and uterovaginal prolapse can also be visualized. Even before the advent of magnetic resonance imaging, barium defecography was not widely used, perhaps because radiologists have limited enthusiasm for the test and the technique was incompletely standardized.⁹³ Some asymptomatic subjects have features of disordered defecation. Methodological limitations to barium defecography (eg, limited reproducibility of anorectal angle measurements) can be minimized by standardized techniques.⁹⁵ Magnetic resonance defecography avoids radiation exposure and is better for visualizing the bony landmarks, which are necessary for measuring pelvic floor motion, than barium defecography; measurements are reproducible among observers.^{59,97} However, in contrast to scintigraphy or fluoroscopy, conventional, closed-configuration magnetic resonance systems permit imaging in the supine position only. With the exception of rectal intussusceptions, for which seated magnetic resonance imaging was superior,⁹⁸ supine and seated magnetic resonance using open-configuration magnets are comparable for identifying clinically relevant findings. Scintigraphy can quantify evacuation of artificial stools with minimal radiation exposure.⁸⁹ However, anatomic defects may not be as well seen as with barium defecography.

Colonic Transit

Rates at which fecal residue moves through the colon are important determinants of fecal form, which can be categorized from liquid to semi-formed to pellet stools.^{72,99} Bowel cleansing shortens colonic transit but does not affect the characterization of patients as having normal or slow colon transit.¹⁰⁰ Hence, it is not necessary to prepare the colon before evaluating colonic transit. Colonic transit is most commonly and inexpensively measured using radiopaque markers (Sitzmarks; Konsyl Pharmaceuticals, Fort Worth, TX). With the Hinton technique, a capsule containing 24 radiopaque markers is swallowed; normally, less than 5 markers should remain in the colon on an abdominal radiograph (110 keV) 5 days later.¹⁰¹ A more refined approach is to have the patient ingest a capsule containing 24 radiopaque markers on days 1, 2, and 3 and count the markers remaining on a plain abdominal radiograph on days 4 and 7; a total of 68 markers remaining in the colon is normal, whereas >68 markers indicates slow transit.¹⁰² The test is reproducible in simple constipation⁷² but less so in defecatory disorders and colonic inertia.¹⁰³ Hence, as suggested in the algorithm, colonic transit should be reevaluated when necessary.

Less widely used are radionuclide gamma scintigraphy^{49,104} or a wireless pH-pressure capsule.^{105,106} Radiographic and scintigraphic methods correlate well⁷²; scintigraphy requires scanning for 24 or 48 hours versus 5 to 7 days for completing a radiopaque marker assessment.¹⁰² In patients with constipation, the correlation between colonic transit measured by radiopaque markers (on day 5) and the wireless motility-pH capsule is reasonable (correlation coefficient of approximately 0.7).¹⁰⁵ The capsule can also measure colonic motor activity but cannot identify propagation; the clinical utility of assessing colonic motor activity with a capsule is unclear.¹⁰⁶

Colonic Manometry and Barostat Testing

Colonic manometry or barostat-manometric testing should be considered in patients with medically refractory STC.⁴⁵ However, these tests are only available in highly specialized centers with a research interest and their role in management is not well established. Manometry may be conducted under stationary or ambulatory conditions. As detailed in the section on the pathophysiology of STC, a subset of patients with STC has one or more features of colonic motor dysfunctions. A subtotal colectomy should be considered for patients with medically refractory STC who have colonic motor dysfunction but no pelvic floor dysfunction.

This review will not consider tests that are used in clinical research or generally not applicable to practice. These include (1) specific tests of rectal perception of distention or electrical stimuli, (2) electromyography of the external sphincter or puborectalis, and (3) pudendal nerve terminal motor latency. These studies, although of value in highly selected instances or for research purposes, are not part of the standard armamentarium.⁹³ These investigators also point out the potential role of surface electromyograms in the therapeutic mode of biofeedback.

Putting It Together

At the conclusion of the initial clinical evaluation of patients with constipation, it should be possible to tentatively classify patients into one (or possibly more) of the following categories:

1. NTC with normal colonic transit and defecation; some patients in this group have symptoms of IBS (eg, abdominal pain, bloating, and incomplete defecation)
2. STC when pelvic floor function is normal and there is evidence of slow transit
3. Defecatory disorders (anismus/dyssynergia [failure of relaxation] or descending perineal syndrome and other flaccid disorders)
4. Combination of 2 and 3; clinical observations suggest that some patients also have features of IBS
5. Organic constipation (mechanical obstruction or adverse drug effect; Table 2)
6. Secondary constipation (metabolic disorders; Table 3).

The degree to which some or all of the possibilities listed in Table 3 need to be considered will vary greatly. In some instances, treatment will be available for the primary disorder (hypothyroidism, hypercalcemia, rectal stricture, and so on). When treatment for the primary disorder is not available or is inadequate (eg, scleroderma, amyloidosis, neurologic disease), the challenge of adequate symptomatic treatment remains (see the following text). In most instances, at the level of the primary consultation, it will be sufficient to exclude organic and secondary constipation on clinical grounds and to treat symptomatically. Only some cases will require diagnostic studies for constipation.

Medical Management

The treatment algorithms in the medical position statement encapsulate our suggestions. Tables 4 to 6 summarize common over-the-counter laxative agents and newer pharmacologic agents for chronic constipation. Since the last review, some drugs (ie, cisapride and tegaserod) have been withdrawn and others have been introduced. Also, there is new evidence supporting the use of common laxative agents.

Adjunctive Approaches

There is no evidence that constipation can be treated by increasing fluid intake unless there is evidence of dehydration.⁸² There is evidence that increased physical activity is associated with less constipation.^{82,107} Mild physical activity increases intestinal gas clearance and reduces bloating,¹⁰⁸ and moderate to vigorous intensive physical activity (20–60 minutes 3–5 days per week) has been shown to improve symptoms of life and quality of life in IBS.¹⁰⁹ Although some probiotics may accelerate colonic transit, there are limited data on the impact of probiotics on constipation.¹¹⁰

Dietary Fiber Supplementation and Osmotic Laxatives

Systemic reviews suggest that soluble (eg, psyllium or ispaghula) but not insoluble dietary fiber (eg, wheat bran) supplements improve bowel symptoms in chronic constipation¹¹¹ and IBS.¹¹² A review of 4 trials, of which the largest enrolled 201 patients¹¹³ and 3 used psyllium, showed that soluble dietary fiber improved individual bowel symptoms (eg, stool frequency, straining, stool consistency, and sense of incomplete evacuation) in chronic constipation.¹¹¹ However, only one study treated patients for more than 4 weeks, outcome measurements differed across trials, and none were at low risk for bias, precluding a formal meta-analysis. A meta-analysis of 17 trials observed that soluble fiber improved global symptoms and symptoms of constipation in IBS but that the effects on abdominal pain were variable.¹¹² Thereafter, a randomized study in 275 primary care patients observed superior response rates for psyllium (10 g twice daily; 57%), but not bran, compared with placebo (ie, rice flour; 35%) at 1 month. At 3 months, bran was better than placebo.¹¹⁴ More than 60% of patients randomized to treatment with bran or psyllium reported adverse effects, primarily constipation or diarrhea. Dropout rates for all reasons at 2- and 3-month follow-up were 29% and 40%, respectively. Taken together, the potential therapeutic benefits, low cost, safety profile, and other potential health benefits of dietary fiber justify consideration of fiber supplementation, either as a standardized fiber supplement (Table 4) or through the diet (Table 5), as a first step in patients with chronic constipation, particularly in primary care. In contrast to NTC, patients with drug-induced constipation or STC are unlikely to respond to fiber supplementation.¹¹⁵ Patients should be instructed to begin with 2 daily doses with fluids and/or meals and gradually adjust the dose after a 7- to 10-day period. They should not expect an immediate response (as can be expected with a purgative) but should embark on a program for several weeks. They should also be warned that fiber supplements may increase gaseousness but that the symptoms often decrease after several days. Sometimes gaseousness can be reduced by switching to another fiber supplement.

If more treatment is needed, an inexpensive osmotic agent should be used regularly, supplemented by stimulant laxatives as needed (ie, “rescue” agents). Although there are no head-to-head comparisons of osmotic and stimulant laxatives, osmotic agents may be preferable to stimulant laxatives in patients in whom both agents are equally effective because there is more evidence of short-term and long-term efficacy for certain osmotic agents (ie, polyethylene glycol [PEG]). A meta-analysis of 7 controlled studies (ie, 1141 subjects) evaluating osmotic and stimulant laxatives in chronic idiopathic constipation reported a number needed to treat of 3 (95% confidence interval, 2–4).² The 4 main types of osmotic agents include PEG-based solutions, magnesium citrate–based products, sodium phosphate–based products, and nonabsorbable carbohydrates. These hypertonic products extract fluid into the intestinal lumen by osmosis, causing diarrhea. However, the PEG and electrolyte lavage solution used for colonic cleansing, typically not for chronic constipation, is iso-osmotic with plasma; bowel evacuation is by high-volume lavage. Patients can often titrate the dose of these agents such that soft but not liquid stools are achieved. The most evidence supporting efficacy, including a controlled trial with a duration of 6 months, exists for PEG.^{2,116–118} Although the marketing label recommends treatment with PEG for a

maximum duration of 2 weeks, retrospective series confirm that PEG maintains its efficacy for up to 24 months of treatment.^{117,119} Patients prefer PEG preparations without electrolyte supplements¹²⁰; the electrolyte-containing preparation is mainly indicated when a large volume is used for colonic cleansing.¹²¹ Magnesium hydroxide and other salts improve stool frequency and consistency. Absorption of magnesium is limited, and these agents are generally safe. However, there are a few case reports of severe hypermagnesemia after use of magnesium-based cathartics in patients with renal impairment.¹²² Sodium phosphate-based bowel cleansing preparations should be avoided because they are associated with hyperphosphatemia, hypocalcemia, and hypokalemia and, in less than 1 in 1000 individuals, with acute phosphate nephropathy.^{122,123}

In a Cochrane Database review of 10 randomized trials comparing PEG and lactulose, PEG was superior to lactulose for improving stool frequency, stool consistency, and abdominal pain.¹²⁴ Among nonabsorbable carbohydrates, lactulose and sorbitol had similar laxative effects but lactulose was associated with more nausea in a randomized crossover study of 30 men¹²⁵; sorbitol is less sweet than lactulose and accelerates proximal colonic emptying.^{126,127} Bacterial metabolism of unabsorbed carbohydrate leads to gas production.

Stimulant laxatives (eg, bisacodyl, glycerin suppositories, and sodium picosulfate, which is available in Germany) induce propagated colonic contractions and seem safe even with long-term use; bisacodyl and sodium picosulfate also have antiabsorptive plus secretory effects.^{118,128–130} These agents may be used as rescue agents (eg, if patients do not have a bowel movement for 2 days)¹³¹ or more regularly if required. If stimulant suppositories are used, it seems rational to administer them 30 minutes after breakfast in an attempt to synchronize the pharmacologic agent with the gastrocolonic response. In a multicenter study of 468 patients with chronic constipation, sodium picosulfate improved not only stool frequency and consistency but also other symptoms (eg, ease of evacuation) and quality of life compared with placebo.¹¹⁸ Moreover, abdominal pain was not a major concern (5.6% of patients treated with sodium picosulfate vs 2.2% receiving placebo). Smaller studies suggest that bisacodyl, which works by a mechanism similar to that of sodium picosulfate, is also effective.^{131,132} Contrary to earlier studies,^{133,134} stimulant laxatives (senna, bisacodyl) do not appear to damage the enteric nervous system.^{135,136} Neurologic damage might just as readily be the cause, not the result,¹³⁷ and there is now much less reticence to condone long-term use of stimulants.

Among older drugs, one small phase 2 study suggests that the cholinesterase inhibitor pyridostigmine improved symptoms and accelerated colonic transit in patients with type 2 diabetes mellitus and constipation.¹³⁸ Cisapride and tegaserod have been withdrawn from the marketplace because of concerns related to cardiovascular safety. Colchicine, which is a cytotoxin used to treat gout and produces diarrhea, should also be avoided because it can cause major neuromuscular complications, particularly when renal function is impaired.^{139,140} Although the evidence is very small (ie, one crossover study in 9 patients with active treatment, washout, and placebo periods of 1 week each), the prostaglandin E₁ analogue misoprostol, which increases gastrointestinal secretion, has been used to manage constipation.¹⁴¹ Three new classes of agents to manage chronic constipation include intestinal secretagogues and serotonin 5-HT₄ receptor agonists for NTC and STC as well as opioid antagonists, which are specifically developed for opioid-induced constipation.

Intestinal Secretagogues

By stimulating net efflux of ions and water into the intestinal lumen, secretagogues accelerate transit and also facilitate ease of defecation. Both secretagogues for chronic constipation (ie, lubiprostone and linaclotide) increase intestinal chloride secretion by activating channels on the apical (luminal) enterocyte surface (Table 5). To maintain

electroneutrality, sodium is also secreted into the intestinal lumen by other ion channels and transporters. Water secretion follows. Lubiprostone is a bicyclic fatty acid derivative derived from prostaglandin E₁¹⁴² that primarily works by activating apical Cl⁻ channels. Lubiprostone also activates prostaglandin EP receptors and the apical cystic fibrosis transmembrane regulator (CFTR); the latter also mediates intestinal fluid secretion.^{143,144} These secretory effects likely explain why lubiprostone accelerates small intestinal and colonic transit in healthy subjects.¹⁴⁵ Lubiprostone does not affect colonic motor activity in health.¹⁴⁶ Based on studies summarized by Ford and Suares² and Schey and Rao,¹⁴² lubiprostone is approved by the Food and Drug Administration (FDA) at a dosage of 24 µg twice daily for the treatment of chronic constipation and at a lower dosage (8 µg twice daily) for the treatment of women with IBS-C (Table 6). Women of childbearing age should have a negative pregnancy test result before starting treatment and should be capable of complying with effective contraceptive measures.

Linaclotide is a first-in-class 14-amino acid peptide homologous to the heat-stable enterotoxins that cause diarrhea.¹⁴⁷ These heat-stable enterotoxins are also 3-disulfide homologues of the endogenous 2-disulfide paracrine hormones uroguanylin in the small intestine and guanylin in the colon. These compounds act on guanylyl cyclase C, which is selectively expressed in brush border membranes of intestinal mucosa cells from the duodenum to the rectum. Linaclotide activates the intracellular catalytic domain of guanylyl cyclase C, which in turn converts guanosine triphosphate to cyclic guanosine monophosphate, inducing downstream effectors that phosphorylate the CFTR, which opens the CFTR chloride channel and produces a net efflux of ions and water into the intestinal lumen. Linaclotide has minimal oral bioavailability and extraintestinal adverse effects, and it improved symptoms in phase 3 trials in chronic constipation^{2,148} and in phase 2 trials in IBS-C.¹⁴⁹ Linaclotide also accelerated colonic transit in patients with IBS-C.¹⁵⁰ The FDA recently approved linaclotide for treating IBS-C and chronic constipation in adults at dosages of 290 and 145 µg daily, respectively. The FDA approval letter also requested additional toxicology studies to better understand why linaclotide caused deaths in neonatal and young juvenile mice but not in older juvenile mice.

Serotonin 5-HT₄ Receptor Agonists

Serotonin 5-HT₄ receptors are widely distributed on enteric neurons. 5-HT₄ receptor agonists induce fast excitatory postsynaptic potentials in intrinsic neurons, release neurotransmitters such as the excitatory acetylcholine, and induce mucosal secretion by activating submucosal neurons. None of the 3 new high-selectivity affinity 5-HT₄ receptor agonists (ie, prucalopride, velusetrag, and ATI-7505) are approved by the FDA. Compared with older 5-HT₄ agonists, they have a much higher selectivity and affinity for 5-HT₄ receptors (Table 6). For example, in contrast to tegaserod, it is unlikely that these newer agents have antagonistic effects at 5-HT_{2B} receptors, which may have vascular effects. Also, extensive cardiovascular safety assessments suggest that these compounds do not affect hERG channels or the QTc interval and do not have arrhythmic effects.

Among the 5-HT₄ agonists for chronic constipation, the most evidence in humans is available for prucalopride. Prucalopride accelerated gastrointestinal and colonic transit in constipation,¹⁵¹ and data from 7 randomized controlled trials with 2639 patients showed its efficacy in chronic constipation.² The European Agency for Evaluation of Medicinal Products approved the medication for chronic constipation in women in whom laxatives fail to provide adequate relief at a dosage of 2 mg/day in adults and 1 mg/day in the elderly.^{152–155}

Bile Acid Transporter Inhibitors

Bile acids, which are not absorbed in the terminal ileum, spill over into the colon, where they are deconjugated and dehydroxylated by colonic microbiota to produce secondary bile acids such as deoxycholic acid, which induce colonic secretion.¹⁵⁶ This phenomenon, which is referred to as choleraic diarrhea, is minimized by ileal bile acid transporters, which normally absorb 97% of bile acids. Following up on a small pilot study,¹⁵⁷ phase 2 studies showed that the ileal bile acid transporter inhibitor A3309 accelerated colonic transit¹⁵⁸ and improved bowel habits in chronic constipation.¹⁵⁹ Responses, as defined by an increase of

1 complete spontaneous bowel movements per week over baseline during 4 of 8 treatment weeks, were more frequently observed with A3309 (ie, 58%, 64%, and 75% with the 5-, 10-, and 15-mg doses, respectively) than placebo (33%). The 2 higher doses (10 and 15 mg) significantly improved straining, bloating, and the Bristol Stool Form Scale score from about 2 at baseline to approximately 4 following treatment. Although A3309 was well tolerated, abdominal cramps (27%) and diarrhea (12.5%) were common with the 15-mg dose, and 23% of the patients in this group withdrew from the study. Thus, the 10-mg daily dosage seems to provide the optimum benefit-to-risk ratio for A3309. In addition to improving bowel habits, A3309 also dose-dependently lowered total and low-density lipoprotein cholesterol levels, which may be particularly beneficial for older patients with chronic constipation. Although promising, these results need to be confirmed by larger phase 3 trials.

Comparison of Pharmacologic Agents for Chronic Constipation

Consistent with recent reviews, this technical review recommends a therapeutic trial of traditional approaches (ie, fiber supplementation, osmotic laxatives, stimulant laxatives), which are effective, safe, and generally inexpensive, before newer agents (secretagogues, serotonin 5-HT₄ receptor agonists) are considered for managing chronic constipation.³ Meta-analyses,² systematic reviews,¹¹¹ and the only head-to-head comparative study¹⁶⁰ suggested that some traditional approaches are as effective as newer agents for treating patients with chronic constipation (Table 6). Table 6 utilizes the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, which is based on the quality of evidence and magnitude of benefit, to grade therapies into 4 categories (ie, high, moderate, low, or very low).¹⁶¹ Several points deserve emphasis. First, end points differed across studies; hence, these numbers may not be strictly comparable. For example, most trials with prucalopride and linaclotide have been anchored by complete spontaneous bowel movements, whereas the studies of lubiprostone were anchored by complete, not spontaneous, bowel movements. However, the criteria for therapeutic response were more stringent in the latter. Second, with the exception of soluble fiber, there is more evidence for efficacy in chronic constipation than in IBS-C. Although lubiprostone and linaclotide have been used in patients with IBS-C, there are no large high-quality trials of PEG, other osmotic or stimulant laxatives, or prucalopride in patients with IBS-C. Nonetheless, based on indirect evidence (ie, the mechanism of action of these agents and clinical experience suggesting efficacy in IBS-C), these agents are probably effective also in patients with IBS-C; the grade has been downgraded by a notch to reflect a lack of direct evidence. Third, the evidence for efficacy is strongest for osmotic and stimulant laxatives. Fourth, there are several well-designed clinical trials showing that lubiprostone, linaclotide, and prucalopride are efficacious for patients with chronic constipation and that lubiprostone and linaclotide are also efficacious for patients with IBS. The evidence to support the use of these newer agents for these indications is rated as moderate, primarily because (1) the pooled estimate of the magnitude of reduced risk (ie, for treatment vs placebo), as suggested by the upper bound of the 95th percentile confidence interval, was relatively low (ie, 12% for prucalopride, 20% for lubiprostone, and 13% for linaclotide) in chronic constipation and (2) the 95% confidence interval for reduced risk was relatively wide or imprecise for

lubiprostone in chronic constipation and IBS-C. Fifth, because refractoriness to traditional agents (eg, laxatives) was not, with the exception of several studies with prucalopride, an entry criterion in most studies, the incremental utility of newer agents over traditional approaches, which is the critical question in clinical practice, requires further study. Sixth, anorectal functions and colonic transit were not evaluated in most therapeutic trials; hence, it is unclear if an inadequate response to therapy can be explained by pelvic floor dysfunctions or colonic motor dysfunctions.

Management of Defecatory Disorders

Defecatory disorders should be managed by biofeedback-aided pelvic floor retraining. Using visual or auditory feedback of anorectal and pelvic floor muscle activity, which are typically recorded by surface electromyographic sensors or manometry, patients learn to appropriately increase intra-abdominal pressure and relax the pelvic floor muscles during defecation. Thereafter, patients practice by expelling an air-filled balloon, assisted if necessary by the application of external traction to a catheter attached to the balloon. In patients with reduced rectal sensation, sensory retraining, in which patients learn to recognize weaker sensations of rectal filling, may also be provided. Although therapy may also include measures to improve pelvic floor contraction (ie, Kegel exercises), the emphasis in patients with defecatory disorders is on appropriately coordinating abdominal and pelvic floor motion during evacuation.

Regrettably, biofeedback therapy is not widely used to manage defecatory disorders, perhaps primarily because the benefits of pelvic floor retraining, as shown by controlled trials, are not widely recognized and the expertise is not widely available. Contrary to an earlier study,¹⁶² more recent controlled trials show that pelvic floor retraining is more effective in defecatory disorders, as evidenced by an abnormal rectal balloon expulsion test result, than in isolated STC; 71% of patients with dyssynergic defecation but only 8% of patients with isolated STC achieved adequate relief after biofeedback therapy⁵⁷ (Table 7). Moreover, colonic transit normalized after biofeedback therapy in 65% of patients with disordered defecation but only 8% of patients with STC, reinforcing the concept that delayed colonic transit may be secondary to pelvic floor dysfunction.⁵⁷ Three controlled studies showed that biofeedback therapy is more effective than PEG,¹⁶³ sham feedback,¹⁶⁴ or diazepam¹⁶⁵ in defecatory disorders. These trials used 5 to 6 training sessions lasting 30 to 60 minutes at 2 weekly intervals. Alternatively, daily sessions can be provided over a shorter duration. The skill and experience of the therapist and the patient's motivation are critical factors influencing the response to biofeedback therapy. Dietitians and behavioral psychologists should also participate in this therapy as necessary. Third-party coverage for biofeedback therapy in defecatory disorders has improved over time. For example, the Centers for Medicare & Medicaid Services in many regions now consider biofeedback therapy as medically necessary for treating adults with severe constipation due to pelvic floor dysfunction that has not responded to more conservative treatment measures. When biofeedback therapy is denied for patients with defecatory disorders, physicians should strongly consider appealing the decision because many insurance carriers have not reviewed their policies since the advent of controlled studies showing that pelvic floor retraining is more effective than laxatives for defecatory disorders.

Role of Surgery

Surgical intervention in patients with constipation is generally divided into procedures for documented STC and those for defecatory disorders. Patients should be referred to surgery only after nonsurgical measures have failed and symptoms compromise activities of daily living.

Subtotal Colectomy for STC

Abdominal colectomy and ileorectal anastomosis (IRA) should be strongly considered in patients with medically refractory STC who do not have pelvic floor dysfunction or a diffuse upper gastrointestinal dysmotility.³⁷⁻³⁹ Importantly, patients are advised that IRA treats the primary symptoms of constipation (infrequent and difficult evacuation) but may not improve other symptoms, such as abdominal pain and bloating, which patients associate with constipation but often persist postoperatively. This observation likely partially explains the quite variable outcomes seen in many series of patients who underwent procedures in the 1980s and 1990s. Moreover, in most of these same studies, patients did not undergo objective tests of pelvic floor function or tests that quantified colonic transit; patients thus underwent procedures for “undocumented” constipation and may instead have had IBS-C, which is poorly managed by IRA (see the following text).

The colon is removed to the level of the sacral promontory, the rectum is elevated carefully to preserve the presacral nerves, and the anastomosis is made to the highest third of the rectum.^{37,39} Anastomosis to the sigmoid colon results invariably in persistence or recurrence of STC,³⁷ while conversely, an anastomosis to the middle or lower third of the rectum may result in high stool frequencies and sometimes fecal incontinence.

Controversy exists regarding hemicolectomy and targeted segmental resection for STC. Although results for IRA are superior to those for segmental colectomy in several studies, 2 small studies in patients in whom left, right, or subtotal colectomy^{37-39,166} based on segmental transit time measurements were performed reported good results.^{167,168}

In properly selected patients, prompt and sustained relief of STC is achieved by IRA.^{37-39,166,169,170} A nonrobust outcome measure, “satisfaction,” is reported in between 90% and 100% of patients after IRA.^{37,166,167,171} Recently, quality of life results after IRA for STC using validated outcome measures showed impressive results that were sustained over time.¹⁶⁶ In general, poorer outcomes in terms of satisfaction are reported by investigators who did not perform complete physiological assessments of their patients; patients with delayed colonic transit and no pelvic floor dysfunction report higher rates of satisfaction and better function^{37,39,167} than those who underwent surgery based on history and physical examinations alone.^{172,173} Several series have established the safety and efficacy of performing abdominal colectomy and ileorectostomy using either purely laparoscopic or hand-assisted techniques.¹⁷⁴⁻¹⁷⁶ Counterbalancing increased operative time is the cosmetic advantage of tiny incisions and accelerated recovery times in this generally younger cohort of patients. Although we found that patients with STC and concomitant upper gastrointestinal dysmotility did well after IRA,¹⁷⁷ others have cautioned against this approach.^{173,178}

Complications occur in patients undergoing IRA for constipation, just as they can occur in any patient undergoing abdominal surgery; ileus, small bowel obstruction, anastomotic leakage, and wound infections all occur, but not at rates any higher than expected.^{37,166} Small bowel obstruction is the most common complication after IRA, occurring in 10% to 70% of patients,^{37,179} and can affect patients either early or late in their postoperative course. Most such episodes are managed conservatively and do not require reoperation.

Finally, there have been no objective predictors of success identified in patients with STC undergoing IRA, although outcomes in properly selected patients have been predictably good.¹⁶⁶

Other Surgical Approaches for STC

Antegrade colonic enemas¹⁸⁰ ensure colonic emptying by infusing water into the colon either through an appendiceal conduit or indwelling cecostomy catheter.^{180,181} This procedure has been mostly used in children with neurogenic constipation, and there is limited experience in adults.¹⁸² In patients with severe bloating and abdominal pain accompanying STC, a venting ileostomy may help ascertain if symptoms are attributable to the small intestine or colon. If symptoms do not improve with a venting ileostomy, an IRA would not be indicated.¹⁸³ Constructing colectomies instead of ileostomies in these situations is ill advised, because colonic transit is slow and persistent constipation may occur.

Sacral Nerve Stimulation

The use of sacral nerve stimulation to treat the symptoms of constipation (caused by slow transit, pelvic floor dysfunction, or both) has gained credence in Europe as experience has widened. In the largest and multicenter study, 45 of 62 patients with medically refractory chronic constipation proceeded to permanent stimulation; 39 patients had improved symptoms (ie, 50% reduction in straining during defecation, sense of incomplete evacuation after defecation, or an increase in bowel frequency from less than 3 to 3 or more bowel movements per week).¹⁸⁴ Of 27 patients in whom colonic transit was evaluated at baseline, 20 had delayed colonic transit; only 9 had delayed transit after therapy.¹⁸⁴ In contrast, another study of 19 patients reported that only 42% of patients with a mix of slow transit and pelvic floor dysfunction had improved symptoms with sacral nerve stimulation.¹⁸⁵ Moreover, approximately 60% of patients undergoing sacral nerve stimulation for constipation experienced one or more “events”; the 2 most common were loss of efficacy and pain.¹⁸⁶ More than one-third of patients required surgical reintervention or discontinuation of treatment altogether.¹⁸⁶ Sacral nerve stimulation for the treatment of constipation is not approved by the FDA for use in the United States.

Surgery and Pelvic Floor Injection of Botulinum Toxin for Pelvic Floor Dysfunction

Older surgical approaches addressing pelvic floor dysfunction (anismus, paradoxical puborectal muscle contraction) consisted of dividing the puborectalis muscle or performing a postanal repair.^{187,188} Neither is effective. Based on small, uncontrolled studies, injection of botulinum toxin into the puborectalis muscle, which is variably effective,^{189,190} cannot be recommended for managing defecatory disorders.

Stapled Transanal Resection

The stapled transanal resection (STARR) procedure was developed to address the problem of obstructed defecation caused by 2 anatomic abnormalities: rectal intussusception (occult rectal prolapse) and rectoceles. Rectoceles traditionally are managed operatively if the defect is large, fills preferentially on a defecating proctogram, and is managed by the patient stenting the posterior wall of the vagina.¹⁹¹ Rectal intussusception has traditionally been treated by pelvic floor retraining for lack of an efficacious alternative.^{192,193}

The STARR procedure involves stapling the redundant rectal mucosa associated with a rectocele and intussusception. The aim is to cure the symptoms by resecting the redundant tissue, but the link between symptoms and actual anatomic abnormalities is tenuous.¹⁹⁴ It is quite probable that anatomic abnormalities, such as intussusception and complete rectal prolapse, are actually caused by the underlying disorder of function (impaired pelvic floor relaxation and excessive straining), which is not corrected by the procedure. Although a large randomized, prospective, multicenter trial observed that STARR was superior to pelvic floor retraining using biofeedback therapy, it is unclear what proportion of patients had

pelvic floor dysfunction at baseline because rectal balloon expulsion was not evaluated at baseline; anal pressures were measured but not provided.¹⁹⁵ There are discrepancies between improvement in symptoms and anatomy; symptoms may improve despite modest effects on anatomic disturbances^{196–198} and vice versa.¹⁹⁹

Complications include pelvic sepsis, fistula, peritonitis, bowel perforation, pain, and bleeding,^{197,200,201} which has prompted pleas that only qualified surgeons perform STARR.²⁰¹ Finally, the long-term outcomes of patients even ideally suited for STARR are somewhat disappointing.²⁰² The operation has failed to gain widespread acceptance in the United States.

Pouch of Douglas protrusion,²⁰³ which is often confused with rectal intussusception and full-thickness rectal prolapse, is best addressed with sacrocolpopexy and is usually performed in conjunction with other gynecologic procedures in patients with pelvic floor abnormalities such as cystoceles, rectoceles, and enteroceles and vaginal vault prolapse.²⁰⁴

Summary of the Surgical Approach to Patients With Constipation (Grade of Recommendation)

Patients with STC who fail to respond to optimal medical management are candidates for colectomy and ileorectostomy. In a referred population undergoing stringent physiological testing, only about 3% are actually candidates for this procedure. Thus, among the population at large with constipation, only a tiny fraction will ever be suitable candidates for ileorectostomy. Patients with both pelvic floor dysfunction and STC should have their pelvic floor function addressed by pelvic floor retraining and, if constipation persists, should be offered IRA.³⁹ Patients with pelvic floor dysfunction alone should undergo pelvic floor retraining, patients with a physiologically significant rectocele should undergo a repair, and patients with rectal intussusception should undergo pelvic floor retraining. Until STARR becomes a safe, reproducible, effective, and durable procedure, it should be performed on a protocol basis.

Conclusions

Based on the preceding review, an algorithmic approach to patients with constipation can be devised. See Algorithms 1 to 3 in the preceding medical position statement.

After the initial history and physical examination, it should be provisionally possible to classify patients into one of several subgroups. Standard blood tests (complete blood cell count, thyroid-stimulating hormone, calcium) are widely used and inexpensive. The yield of these tests has not been evaluated but is likely very low. Whether these tests should be routinely performed in all patients is debatable. When appropriate, a colonic structural evaluation (colonoscopy or flexible sigmoidoscopy and barium enema or computed tomographic colonography) should be performed to rule out organic causes of the constipation. Patients with known neurologic conditions need these to be addressed. If the initial evaluation is normal or negative, an empiric trial of fiber (and/or dietary changes) can be followed by over-the-counter osmotic or stimulant laxatives. Most patients will obtain symptom relief with these measures, which are safe for long-term use.²⁰⁵ Patients who fail to respond to this initial approach are appropriate candidates for more specialized testing. Pelvic floor dysfunction needs to be excluded by performing anorectal manometry and a balloon expulsion study, followed by defecography if necessary. Biofeedback therapy is the cornerstone for managing pelvic floor dysfunction. A simple and inexpensive radiopaque marker study will identify STC, which should be treated with aggressive laxative programs and, where available, prokinetic agents. Truly refractory patients may be considered for surgery, although few will qualify after more extensive physiological studies.

Many patients will have normal studies, and most will meet the criteria for IBS-C. The hope is that most of these patients can be managed with laxatives and reassurance. As with other functional gastrointestinal disorders, psychological conditions need to be considered as contributing factors. Key to their adequate management is identification of the predominant symptom: is this constipation or the associated symptoms (bloating, pain, nausea, and so on)?

Unfortunately, the clinical effectiveness and the cost-effectiveness of this algorithmic approach have not been assessed. The structural evaluation, at least in older patients, is likely cost-effective on the basis of identifying colon cancer and adenomatous polyps. Laxatives, biofeedback, and surgery have all been shown to be effective in treating selected patients. Community-based physicians will likely perform the evaluation sequentially, whereas tertiary centers may need to test more simultaneously for patient convenience. Many of the specific points of our algorithm may be debated, and different algorithms certainly have not been compared for clinical or cost benefits. The goal of this review was to guide practicing gastroenterologists through rational and efficacious approaches to patients with constipation.

Acknowledgments

The authors thank Dr Yngve Falck-Yitter for considerable assistance with systemically grading the evidence for pharmacologic agents and Lori Anderson for excellent secretarial support.

Funding

Supported in part by grant R01 DK78924 from the National Institutes of Health, U.S. Public Health Service.

Abbreviations used in this paper

AGA	American Gastroenterological Association
CFTR	cystic fibrosis transmembrane regulator
FDA	Food and Drug Administration
IBS	irritable bowel syndrome
IBS-C	constipation-predominant irritable bowel syndrome
IRA	ileorectal anastomosis
NTC	normal transit constipation
STARR	stapled transanal resection
STC	slow transit constipation

References

1. Locke GR III. The epidemiology of functional gastrointestinal disorders in North America. *Gastroenterol Clin North Am.* 1996; 25:1–19. [PubMed: 8682567]
2. Ford A, Suares N. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. *Gut.* 2011; 60:209–218. [PubMed: 21205879]
3. Camilleri M, Bharucha AE. Behavioural and new pharmacological treatments for constipation: getting the balance right. *Gut.* 2010; 59:1288–1296. [PubMed: 20801775]
4. Mugie SM, Benninga MA, Di Lorenzo C. Epidemiology of constipation in children and adults: a systematic review. *Best Pract Res Clin Gastroenterol.* 2011; 25:3–18. [PubMed: 21382575]
5. Sandler RS, Drossman DA. Bowel habits in young adults not seeking health care. *Dig Dis Sci.* 1987; 32:841–845. [PubMed: 3608732]

6. Bharucha AE, Wald A, Enck P, et al. Functional anorectal disorders. *Gastroenterology*. 2006; 130:1510–1518. [PubMed: 16678564]
7. Longstreth G, Thompson W, Chey W, et al. Functional bowel disorders. *Gastroenterology*. 2006; 130:1480–1491. [PubMed: 16678561]
8. Bharucha AE, Locke GR, Zinsmeister AR, et al. Differences between painless and painful constipation among community women. *Am J Gastroenterol*. 2006; 101:604–612. [PubMed: 16464225]
9. He CL, Burgart L, Wang L, et al. Decreased interstitial cell of cajal volume in patients with slow-transit constipation. *Gastroenterology*. 2000; 118:14–21. [PubMed: 10611149]
10. Farrugia G. Interstitial cells of Cajal in health and disease. *Neurogastroenterol Motil*. 2008; 20(Suppl 1):54–63. [PubMed: 18402642]
11. Kinnunen O. Study of constipation in a geriatric hospital, day hospital, old people's home and at home. *Aging (Milano)*. 1991; 3:161–170. [PubMed: 1911905]
12. Wald A, Scarpignato C, Mueller-Lissner S, et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. *Aliment Pharmacol Ther*. 2008; 28:917–930. [PubMed: 18644012]
13. Lu CL, Chang FY, Chen CY, et al. Significance of Rome II-defined functional constipation in Taiwan and comparison with constipation-predominant irritable bowel syndrome. *Aliment Pharmacol Ther*. 2006; 24:429–438. [PubMed: 16842471]
14. Bytzer P, Howell S, Leemon M, et al. Low socioeconomic class is a risk factor for upper and lower gastrointestinal symptoms: a population based study in 15 000 Australian adults. *Gut*. 2001; 49:66–72. [PubMed: 11413112]
15. Sandler RS, Jordan MC, Shelton BJ. Demographic and dietary determinants of constipation in the US population. *Am J Public Health*. 1990; 80:185–189. [PubMed: 2297063]
16. Everhart JE, Go VL, Johannes RS, et al. A longitudinal survey of self-reported bowel habits in the United States. *Dig Dis Sci*. 1989; 34:1153–1162. [PubMed: 2787735]
17. Sonnenberg A, Koch TR. Epidemiology of constipation in the United States. *Dis Colon Rectum*. 1989; 32:1–8. [PubMed: 2910654]
18. Dukas L, Willett WC, Giovannucci EL. Association between physical activity, fiber intake, and other lifestyle variables and constipation in a study of women. *Am J Gastroenterol*. 2003; 98:1790–1796. [PubMed: 12907334]
19. Donald IP, Smith RG, Cruikshank JG, et al. A study of constipation in the elderly living at home. *Gerontology*. 1985; 31:112–118. [PubMed: 2987086]
20. Leroi AM, Bernier C, Watier A, et al. Prevalence of sexual abuse among patients with functional disorders of the lower gastrointestinal tract. *Int J Colorectal Dis*. 1995; 10:200–206. [PubMed: 8568404]
21. Haug TT, Mykletun A, Dahl AA. Are anxiety and depression related to gastrointestinal symptoms in the general population? *Scand J Gastroenterol*. 2002; 37:294–298. [PubMed: 11916191]
22. Whitehead WE, Drinkwater D, Cheskin LJ, et al. Constipation in the elderly living at home. Definition, prevalence, and relationship to lifestyle and health status. *J Am Geriatr Soc*. 1989; 37:423–429. [PubMed: 2539405]
23. Talley NJ, Fleming KC, Evans JM, et al. Constipation in an elderly community: a study of prevalence and potential risk factors. *Am J Gastroenterol*. 1996; 91:19–25. [PubMed: 8561137]
24. van Dijk KN, de Vries CS, van den Berg PB, et al. Constipation as an adverse effect of drug use in nursing home patients: an overestimated risk. *Br J Clin Pharmacol*. 1998; 46:255–261. [PubMed: 9764967]
25. Campbell AJ, Busby WJ, Horwath CC. Factors associated with constipation in a community based sample of people aged 70 years and over. *J Epidemiol Community Health*. 1993; 47:23–26. [PubMed: 8382251]
26. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. *Dig Dis Sci*. 1993; 38:1569–1580. [PubMed: 8359066]
27. Shaheen NJ, Hansen RA, Morgan DR, et al. The burden of gastrointestinal and liver diseases, 2006. *Am J Gastroenterol*. 2006; 101:2128–2138. [PubMed: 16848807]

28. Shah ND, Chitkara DK, Locke GR, et al. Ambulatory care for constipation in the United States, 1993-2004. *Am J Gastroenterol.* 2008; 103:1746–1753. [PubMed: 18557708]
29. Jemal A, Siegel R, Xu J, et al. Cancer statistics. *CA Cancer J Clin.* 2010; 60:277–300. [PubMed: 20610543] 2010 [erratum appears in *CA Cancer J Clin* 2011;61:133–134].
30. Martin BC, Barghout V, Cerulli A. Direct medical costs of constipation in the United States. *Manag Care Interface.* 2006; 19:43–49. [PubMed: 17274481]
31. Choung RS, Branda ME, Chitkara D, et al. Longitudinal direct medical costs associated with constipation in women. *Aliment Pharmacol Ther.* 2010; 33:251–260. [PubMed: 21091523]
32. Rantis PC Jr, Vernava AM III, Daniel GL, et al. Chronic constipation— is the work-up worth the cost? *Dis Colon Rectum.* 1997; 40:280–286. [PubMed: 9118741]
33. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. *Gastroenterology.* 1997; 112:594–642. [PubMed: 9024315] [erratum appears in *Gastroenterology* 1998;114:625 and *Gastroenterology* 1997;112:1060].
34. Ghadirian P, Maisonneuve P, Perret C, et al. Epidemiology of sociodemographic characteristics, lifestyle, medical history, and colon cancer: a case-control study among French Canadians in Montreal. *Cancer Detect Prev.* 1998; 22:396–404. [PubMed: 9727620]
35. Belsey J, Greenfield S, Candy D, et al. Systematic review: impact of constipation on quality of life in adults and children. *Aliment Pharmacol Ther.* 2010; 31:938–949. [PubMed: 20180788]
36. Yost KJ, Haan MN, Levine RA, et al. Comparing SF-36 scores across three groups of women with different health profiles. *Qual Life Res.* 2005; 14:1251–1261. [PubMed: 16047501]
37. Pemberton JH, Rath DM, Ilstrup DM. Evaluation and surgical treatment of severe chronic constipation. *Ann Surg.* 1991; 214:403–411. discussion 411–413. [PubMed: 1953096]
38. Wexner SD, Daniel N, Jagelman DG. Colectomy for constipation: physiologic investigation is the key to success. *Dis Colon Rectum.* 1991; 34:851–856. [PubMed: 1914716]
39. Nyam DC, Pemberton JH, Ilstrup DM, et al. Long-term results of surgery for chronic constipation. *Dis Colon Rectum.* 1997; 40:273–279. [PubMed: 9118740] [erratum appears in *Dis Colon Rectum* 1997;40:529].
40. Mertz H, Naliboff B, Mayer E. Physiology of refractory chronic constipation. *Am J Gastroenterol.* 1999; 94:609–615. [PubMed: 10086639]
41. Preston DM, Lennard-Jones JE. Severe chronic constipation of young women: ‘idiopathic slow transit constipation’. *Gut.* 1986; 27:41–48. [PubMed: 3949236]
42. Rao SS, Welcher KD, Leistikow JS. Obstructive defecation: a failure of rectoanal coordination. *Am J Gastroenterol.* 1998; 93:1042–1050. [PubMed: 9672327]
43. Ravi K, Bharucha AE, Camilleri M, et al. Phenotypic variation of colonic motor functions in chronic constipation. *Gastroenterology.* 2010; 138:89–97. [PubMed: 19660461]
44. Hadley SJ, Walsh BT. Gastrointestinal disturbances in anorexia nervosa and bulimia nervosa. *Curr Drug Targets.* 2003; 2:1–9.
45. Camilleri M, Bharucha AE, di Lorenzo C, et al. American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. *Neurogastroenterol Motil.* 2008; 20:1269–1282. [PubMed: 19019032]
46. Dinning PG, Smith TK, Scott SM. Pathophysiology of colonic causes of chronic constipation. *Neurogastroenterol Motil.* 2009; 21(Suppl 2):20–30. [PubMed: 19824935]
47. Bassotti G. If it is inert, why does it move? *Neurogastroenterol Motil.* 2004; 16:395–396. [PubMed: 15305993]
48. Herve S, Savoye G, Behbahani A, et al. Results of 24-h manometric recording of colonic motor activity with endoluminal instillation of bisacodyl in patients with severe chronic slow transit constipation [see comment]. *Neurogastroenterol Motil.* 2004; 16:397–402. [PubMed: 15305994]
49. Manabe N, Wong BS, Camilleri M, et al. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. *Neurogastroenterol Motil.* 2010; 22:293–e82. [PubMed: 20025692]
50. Lanfranchi GA, Bazzocchi G, Brignola C, et al. Different patterns of intestinal transit time and anorectal motility in painful and painless chronic constipation. *Gut.* 1984; 25:1352–1357. [PubMed: 6510767]

51. Posserud I, Syrous A, Lindstrom L, et al. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. *Gastroenterology*. 2007; 133:1113–1123. [PubMed: 17919487]
52. Mertz H, Naliboff B, Mayer EA. Symptoms and physiology in severe chronic constipation. *Am J Gastroenterol*. 1999; 94:131–138. [PubMed: 9934743]
53. Dinning PG, Hunt L, Lubowski DZ, et al. The impact of laxative use upon symptoms in patients with proven slow transit constipation. *BMC Gastroenterol*. 2011; 11:121. [PubMed: 22073923]
54. Preston DM, Lennard-Jones JE. Anismus in chronic constipation. *Dig Dis Sci*. 1985; 30:413–418. [PubMed: 3987474]
55. Rao SS, Mudipalli RS, Stessman M, et al. Investigation of the utility of colorectal function tests and Rome II criteria in dyssynergic defecation (anismus). *Neurogastroenterol Motil*. 2004; 16:589–596. [PubMed: 15500515]
56. Gladman MA, Lunniss PJ, Scott SM, et al. Rectal hyposensitivity. *Am J Gastroenterol*. 2006; 101:1140–1151. [PubMed: 16696790]
57. Chiarioni G, Salandini L, Whitehead WE. Biofeedback benefits only patients with outlet dysfunction, not patients with isolated slow transit constipation. *Gastroenterology*. 2005; 129:86–97. [PubMed: 16012938]
58. Henry MM, Parks AG, Swash M. The pelvic floor musculature in the descending perineum syndrome. *Br J Surg*. 1982; 69:470–472. [PubMed: 7104636]
59. Bharucha AE, Fletcher JG, Seide B, et al. Phenotypic variation in functional disorders of defecation. *Gastroenterology*. 2005; 128:1199–1210. [PubMed: 15887104]
60. Schweiger M, Alexander-Williams J. Solitary-ulcer syndrome of the rectum: its association with occult rectal prolapse. *Lancet*. 1977; 309:170–171.
61. Parks AG, Swash M, Urich H. Sphincter denervation in anorectal incontinence and rectal prolapse. *Gut*. 1977; 18:656–665. [PubMed: 892613]
62. Bartram CI, Turnbull GK, Lennard-Jones JE. Evacuation proctography: an investigation of rectal expulsion in 20 subjects without defecatory disturbance. *Gastrointest Radiol*. 1988; 13:72–80. [PubMed: 3350272]
63. Jones PN, Lubowski DZ, Swash M, et al. Is paradoxical contraction of puborectalis muscle of functional importance? *Dis Colon Rectum*. 1987; 30:667–670. [PubMed: 3622173]
64. Chiarioni G, Nardo A, Vantini I, et al. Biofeedback is superior to electrogalvanic stimulation and massage for treatment of levator ani syndrome. *Gastroenterology*. 2010; 138:1321–1329. [PubMed: 20044997]
65. Whitehead WE, di Lorenzo C, Leroi AM, et al. Conservative and behavioural management of constipation. *Neurogastroenterol Motil*. 2009; 21(Suppl 2):55–61. [PubMed: 19824938]
66. van Ginkel R, Reitsma JB, Buller HA, et al. Childhood constipation: longitudinal follow-up beyond puberty. *Gastroenterology*. 2003; 125:357–363. [PubMed: 12891536]
67. Klingele CJ, Bharucha AE, Fletcher JG, et al. Pelvic organ prolapse in defecatory disorders. *Obstet Gynecol*. 2005; 106:315–320. [PubMed: 16055581]
68. Zarate N, Knowles CH, Newell M, et al. In patients with slow transit constipation, the pattern of colonic transit delay does not differentiate between those with and without impaired rectal evacuation. *Am J Gastroenterol*. 2008; 103:427–434. [PubMed: 18070233]
69. Law NM, Bharucha AE, Zinsmeister AR. Rectal and colonic distension elicit viscerovisceral reflexes in humans. *Am J Physiol Gastrointest Liver Physiol*. 2002; 283:G384–G389. [PubMed: 12121886]
70. Koch A, Voderholzer WA, Klauser AG, et al. Symptoms in chronic constipation. *Dis Colon Rectum*. 1997; 40:902–906. [PubMed: 9269805]
71. Ratuapli SK, Bharucha AE, Noelting J, et al. Phenotypic identification and classification of functional defecatory disorders using high resolution anorectal manometry. *Gastroenterology*. (in press).
72. Degen LP, Phillips SF. How well does stool form reflect colonic transit? *Gut*. 1996; 39:109–113. [PubMed: 8881820]

73. Saad RJ, Rao SSC, Koch KL, et al. Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. *Am J Gastroenterol.* 2010; 105:403–411. [PubMed: 19888202]
74. Ashraf W, Park F, Lof J, et al. An examination of the reliability of reported stool frequency in the diagnosis of idiopathic constipation. *Am J Gastroenterol.* 1996; 91:26–32. [PubMed: 8561138]
75. Bharucha AE, Seide BM, Zinsmeister AR, et al. Insights into normal and disordered bowel habits from bowel diaries. *Am J Gastroenterol.* 2008; 103:692–698. [PubMed: 18021288]
76. Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. *Am J Gastroenterol.* 2005; 100:1174–1184. [PubMed: 15842596]
77. Talley NJ, Weaver AL, Zinsmeister AR, et al. Functional constipation and outlet delay: a population-based study. *Gastroenterology.* 1993; 105:781–790. [PubMed: 8359649]
78. Neims DM, McNeill J, Giles TR, et al. Incidence of laxative abuse in community and bulimic populations: a descriptive review. *Int J Eat Disord.* 1995; 17:211–228. [PubMed: 7773258]
79. Houghton LA. Bloating in constipation: relevance of intraluminal gas handling. *Best Pract Res Clin Gastroenterol.* 2011; 25:141–150. [PubMed: 21382585]
80. Orkin BA, Sinykin SB, Lloyd PC. The digital rectal examination scoring system (DRESS). *Dis Colon Rectum.* 2010; 53:1656–1660. [PubMed: 21178861]
81. Tantiphlachiva K, Rao P, Attaluri A, et al. Digital rectal examination is a useful tool for identifying patients with dyssynergia. *Clin Gastroenterol Hepatol.* 2010; 8:955–960. [PubMed: 20656061]
82. Muller-Lissner SA, Kamm MA, Scarpignato C, et al. Myths and misconceptions about chronic constipation. *Am J Gastroenterol.* 2005; 100:232–242. [PubMed: 15654804]
83. Pepin C, Ladabaum U. The yield of lower endoscopy in patients with constipation: survey of a university hospital, a public county hospital, and a Veterans Administration medical center. *Gastrointest Endosc.* 2002; 56:325–332. [PubMed: 12196767]
84. Murray JA, Watson T, Clearman B, et al. Effect of a gluten-free diet on gastrointestinal symptoms in celiac disease. *Am J Clin Nutr.* 2004; 79:669–673. [PubMed: 15051613]
85. Walker MM, Murray JA, Ronkainen J, et al. Detection of celiac disease and lymphocytic enteropathy by parallel serology and histopathology in a population-based study. *Gastroenterology.* 2010; 139:112–119. [PubMed: 20398668]
86. Surrenti E, Rath DM, Pemberton JH, et al. Audit of constipation in a tertiary referral gastroenterology practice. *Am J Gastroenterol.* 1995; 90:1471–1475. [PubMed: 7661172]
87. Rao SS, Hatfield R, Soffer E, et al. Manometric tests of anorectal function in healthy adults. *Am J Gastroenterol.* 1999; 94:773–783. [PubMed: 10086665]
88. Noelting J, Ratuapli SK, Bharucha AE, et al. Normal values for high-resolution anorectal manometry in healthy women: effects of age and significance of rectoanal gradient. *Am J Gastroenterol.* 2012; 107:1530–1536. [PubMed: 22986439]
89. Pezim ME, Pemberton JH, Levin KE, et al. Parameters of anorectal and colonic motility in health and in severe constipation. *Dis Colon Rectum.* 1993; 36:484–491. [PubMed: 8482168]
90. Minguez M, Herreros B, Sanchiz V, et al. Predictive value of the balloon expulsion test for excluding the diagnosis of pelvic floor dyssynergia in constipation. *Gastroenterology.* 2004; 126:57–62. [PubMed: 14699488]
91. Shorvon PJ, McHugh S, Diamant NE, et al. Defecography in normal volunteers: results and implications. *Gut.* 1989; 30:1737–1749. [PubMed: 2612988]
92. Faubion SS, Shuster LT, Bharucha AE. Recognition and management of nonrelaxing pelvic floor dysfunction. *Mayo Clin Proc.* 2012; 87:187–193. [PubMed: 22305030]
93. Diamant NE, Kamm MA, Wald A, et al. American Gastroenterological Association medical position statement on anorectal testing techniques. *Gastroenterology.* 1999; 116:732–760. [PubMed: 10029631]
94. Jones MP, Post J, Crowell MD. High-resolution manometry in the evaluation of anorectal disorders: a simultaneous comparison with water-perfused manometry. *Am J Gastroenterol.* 2007; 102:850–855. [PubMed: 17397410]
95. Bharucha AE. Update of tests of colon and rectal structure and function. *J Clin Gastroenterol.* 2006; 40:96–103. [PubMed: 16394868]

96. Agachan F, Pfeifer J, Wexner SD. Defecography and proctography. Results of 744 patients. *Dis Colon Rectum*. 1996; 39:899–905. [PubMed: 8756846]
97. Reiner CS, Tutuiian R, Solopova AE, et al. MR defecography in patients with dyssynergic defecation: spectrum of imaging findings and diagnostic value. *Br J Radiol*. 2011; 84:136–144. [PubMed: 21257836]
98. Bertschinger KM, Hetzer FH, Roos JE, et al. Dynamic MR imaging of the pelvic floor performed with patient sitting in an open-magnet unit versus with patient supine in a closed-magnet unit. *Radiology*. 2002; 223:501–508. [PubMed: 11997560]
99. American Gastroenterological Association. American Gastroenterological Association medical position statement on anorectal testing techniques. *Gastroenterology*. 1999; 116:732–760. [PubMed: 10029631]
100. Sloots CEJ, Felt-Bersma RJF. Effect of bowel cleansing on colonic transit in constipation due to slow transit or evacuation disorder. *Neurogastroenterol Motil*. 2002; 14:55–61. [PubMed: 11874554]
101. Hinton JM, Lennard-Jones JE, Young AC. A new method for studying gut transit times using radioopaque markers. *Gut*. 1969; 10:842–847. [PubMed: 5350110]
102. Metcalf AM, Phillips SF, Zinsmeister AR, et al. Simplified assessment of segmental colonic transit. *Gastroenterology*. 1987; 92:40–47. [PubMed: 3023168]
103. Nam YS, Pikarsky AJ, Wexner SD, et al. Reproducibility of colonic transit study in patients with chronic constipation. *Dis Colon Rectum*. 2001; 44:86–92. [PubMed: 11805568]
104. Burton DD, Camilleri M, Mullan BP, et al. Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. *J Nucl Med*. 1997; 38:1807–1810. [PubMed: 9374360]
105. Rao SS, Kuo B, McCallum RW, et al. Investigation of colonic and whole gut transit with wireless motility capsule and radiopaque markers in constipation. *Clin Gastroenterol Hepatol*. 2009; 7:537–544. [PubMed: 19418602]
106. Hasler WL, Saad RJ, Rao SS, et al. Heightened colon motor activity measured by a wireless capsule in patients with constipation: relation to colon transit and IBS. *Am J Physiol Gastrointest Liver Physiol*. 2009; 297:G1107–G1114. [PubMed: 19808653]
107. De Schryver AM, Samsom M, Smout AI. Effects of a meal and bisacodyl on colonic motility in healthy volunteers and patients with slow-transit constipation. *Dig Dis Sci*. 2003; 48:1206–1212. [PubMed: 12870774]
108. Villoria A, Serra J, Azpiroz F, et al. Physical activity and intestinal gas clearance in patients with bloating. *Am J Gastroenterol*. 2006; 101:2552–2557. [PubMed: 17029608]
109. Johannesson E, Simren M, Strid H, et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. *Am J Gastroenterol*. 2011; 106:915–922. [PubMed: 21206488]
110. Quigley EMM. The enteric microbiota in the pathogenesis and management of constipation. *Best Pract Res Clin Gastroenterol*. 2011; 25:119–126. [PubMed: 21382583]
111. Soares NC, Ford AC. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. *Aliment Pharmacol Ther*. 2011; 33:895–901. [PubMed: 21332763]
112. Bijkerk CJ, Muris JWM, Knottnerus JA, et al. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. *Aliment Pharmacol Ther*. 2004; 19:245–251. [PubMed: 14984370]
113. Fenn GC, Wilkinson PD, Lee CE, et al. A general practice study of the efficacy of Regulan in functional constipation. *Br J Clin Pract*. 1986; 40:192–197. [PubMed: 3530306]
114. Bijkerk CJ, de Wit NJ, Muris JWM, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. *BMJ*. 2009; 339:b3154. [PubMed: 19713235]
115. Voderholzer WA, Schatke W, Muhldorfer BE, et al. Clinical response to dietary fiber treatment of chronic constipation. *Am J Gastroenterol*. 1997; 92:95–98. [PubMed: 8995945]
116. Corazziari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. *Gut*. 2000; 46:522–526. [PubMed: 10716682]

117. DiPalma JA, Cleveland MV, McGowan J, et al. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. *Am J Gastroenterol.* 2007; 102:1436–1441. [PubMed: 17403074]
118. Mueller-Lissner S, Kamm MA, Wald A, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. *Am J Gastroenterol.* 2010; 105:897–903. [PubMed: 20179697]
119. Migeon-Duballet I, Chabin M, Gautier A, et al. Long-term efficacy and cost-effectiveness of polyethylene glycol 3350 plus electrolytes in chronic constipation: a retrospective study in a disabled population. *Curr Med Res Opin.* 2006; 22:1227–1235. [PubMed: 16846556]
120. Szojda MM, Mulder CJJ, Felt-Bersma RJF. Differences in taste between two polyethylene glycol preparations. *J Gastrointest Liver Dis.* 2007; 16:379–381.
121. Di Palma JA, Smith JR, Cleveland MV. Overnight efficacy of polyethylene glycol laxative. *Am J Gastroenterol.* 2002; 97:1776–1779. [PubMed: 12135034]
122. Nyberg C, Hendel J, Nielsen OH. The safety of osmotically acting cathartics in colonic cleansing. *Nat Rev Gastroenterol Hepatol.* 2010; 7:557–564. [PubMed: 20736921]
123. Ainley EJ, Winwood PJ, Begley JP. Measurement of serum electrolytes and phosphate after sodium phosphate colonoscopy bowel preparation: an evaluation. *Dig Dis Sci.* 2005; 50:1319–1323. [PubMed: 16047480]
124. Lee-Robichaud H, Thomas K, Morgan J, et al. Lactulose versus polyethylene glycol for chronic constipation. *Cochrane Database Syst Rev.* 2010; 7:CD007570. [PubMed: 20614462]
125. Lederle FA, Busch DL, Mattox KM, et al. Cost-effective treatment of constipation in the elderly: a randomized double-blind comparison of sorbitol and lactulose. *Am J Med.* 1990; 89:597–601. [PubMed: 2122724]
126. Wesselius-De Casparis A, Braadbaart S, Bergh-Bohlken GE, et al. Treatment of chronic constipation with lactulose syrup: results of a double-blind study. *Gut.* 1968; 9:84–86. [PubMed: 4867936]
127. Skoog SM, Bharucha AE, Camilleri M, et al. Effects of an osmotically active agent on colonic transit. *Neurogastroenterol Motil.* 2006; 18:300–306. [PubMed: 16553585]
128. Louvel D, Delvaux M, Staumont G, et al. Intracolonic injection of glycerol: a model for abdominal pain in irritable bowel syndrome? *Gastroenterology.* 1996; 110:351–361. [PubMed: 8566580]
129. Ewe K, Holker B. The effect of a diphenolic laxative (Bisacodyl) on water- and electrolyte transport in the human colon [author's translation]. *Klin Wochenschr.* 1974; 52:827–833. [PubMed: 4449188]
130. Manabe N, Cremonini F, Camilleri M, et al. Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. *Aliment Pharmacol Ther.* 2009; 30:930–936. [PubMed: 19678812]
131. Kamm M, Mueller-Lissner S, Wald A, et al. Stimulant laxatives are effective in chronic constipation: multi-center, 4-week, double-blind, randomized, placebo-controlled trial of bisacodyl. *Gastroenterology.* 2010; 138(Suppl 1):S228.
132. Kienzle-Horn S, Vix JM, Schuijt C, et al. Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study. *Aliment Pharmacol Ther.* 2006; 23:1479–1488. [PubMed: 16669963]
133. Smith B. Effect of irritant purgatives on the myenteric plexus in man and the mouse. *Gut.* 1968; 9:139–143. [PubMed: 5655023]
134. Smith B. Pathologic changes in the colon produced by anthraquinone purgatives. *Dis Colon Rectum.* 1973; 16:455–458. [PubMed: 4769219]
135. Dufour P, Gendre P. Ultrastructure of mouse intestinal mucosa and changes observed after long term anthraquinone administration. *Gut.* 1984; 25:1358–1363. [PubMed: 6510768]
136. Kiernan JA, Heinicke EA. Sennosides do not kill myenteric neurons in the colon of the rat or mouse. *Neuroscience.* 1989; 30:837–842. [PubMed: 2570374]
137. Leon SH, Krishnamurthy S, Schuffler MD. Subtotal colectomy for severe idiopathic constipation. A follow-up study of 13 patients. *Dig Dis Sci.* 1987; 32:1249–1254. [PubMed: 2444400]

138. Bharucha AE, Low P, Camilleri M, et al. A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. *Gut*. Jun 7.2012 [Epub ahead of print].
139. Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. *N Engl J Med*. 1987; 316:1562–1568. [PubMed: 3035372]
140. Verne GN, Eaker EY, Davis RH, et al. Colchicine is an effective treatment for patients with chronic constipation: an open-label trial. *Dig Dis Sci*. 1997; 42:1959–1963. [PubMed: 9331162]
141. Soffer EE, Metcalf A, Launspach J. Misoprostol is effective treatment for patients with severe chronic constipation. *Dig Dis Sci*. 1994; 39:929–933. [PubMed: 8174433]
142. Schey R, Rao SSC. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. *Dig Dis Sci*. 2011; 56:1619–1625. [PubMed: 21523369]
143. Bassil AK, Borman RA, Jarvie EM, et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. *Br J Pharmacol*. 2008; 154:126–135. [PubMed: 18332851]
144. Ao M, Venkatasubramanian J, Boonkaewwan C, et al. Lubiprostone activates Cl⁻ secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84. *Dig Dis Sci*. 2011; 56:339–351. [PubMed: 21140215]
145. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. *Am J Physiol Gastrointestinal Liver Physiol*. 2006; 290:G942–G947.
146. Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. *Am J Physiol Gastrointestinal Liver Physiol*. 2009; 296:G295–G301.
147. Bharucha AE, Waldman SA. Taking a lesson from microbial diarrheagenesis in the management of chronic constipation. *Gastroenterology*. 2010; 138:813–817. [PubMed: 20114092]
148. Lembo AJ, Kurtz CB, MacDougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. *Gastroenterology*. 2010; 138:886–895. [PubMed: 20045700]
149. Johnston JM, Kurtz CB, MacDougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. *Gastroenterology*. 2010; 139:1877–1886. [PubMed: 20801122]
150. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. *Gastroenterology*. 2007; 133:761–768. [PubMed: 17854590]
151. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. *Gastroenterology*. 2001; 120:354–360. [PubMed: 11159875]
152. Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. *N Engl J Med*. 2008; 358:2344–2354. [PubMed: 18509121]
153. Quigley EMM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation—a 12-week, randomized, double-blind, placebo-controlled study. *Aliment Pharmacol Ther*. 2009; 29:315–328. [PubMed: 19035970]
154. Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. *Gut*. 2009; 58:357–365. [PubMed: 18987031]
155. Muller-Lissner S, Rykx A, Kerstens R, et al. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. *Neurogastroenterol Motil*. 2010; 22:991–998. [PubMed: 20529205]
156. Mekjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. *J Clin Invest*. 1971; 50:1569–1577. [PubMed: 4938344]
157. Simrén M, Bajor A, Gillberg PG, et al. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation – a double-blind study. *Aliment Pharmacol Ther*. 2011; 34:41–50. [PubMed: 21545606]

158. Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. *Am J Gastroenterol.* 2011; 106:2154–2164. [PubMed: 21876564]
159. Chey WD, Camilleri M, Chang L, et al. A randomized placebo-controlled phase IIb trial of A3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. *Am J Gastroenterol.* 2011; 106:1803–1812. [PubMed: 21606974]
160. Di Palma JA, Cleveland MV, McGowan J, et al. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. *Am J Gastroenterol.* 2007; 102:1964–1971. [PubMed: 17573794]
161. Falck-Ytter Y, Kunz R, Guyatt GH, et al. How strong is the evidence? *Am J Gastroenterol.* 2008; 103:1334–1338. [PubMed: 18547222]
162. Chiotakakou-Faliakou E, Kamm MA, Roy AJ, et al. Biofeedback provides long-term benefit for patients with intractable, slow and normal transit constipation. *Gut.* 1998; 42:517–521. [PubMed: 9616314]
163. Chiarioni G, Whitehead WE, Pezza V, et al. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. *Gastroenterology.* 2006; 130:657–664. [PubMed: 16530506]
164. Rao SS, Seaton K, Miller M, et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. *Clin Gastroenterol Hepatol.* 2007; 5:331–338. [PubMed: 17368232]
165. Heymen S, Scarlett Y, Jones K, et al. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. *Dis Colon Rectum.* 2007; 50:428–441. [PubMed: 17294322]
166. Hassan I, Pemberton JH, Young-Fadok TM, et al. Ileorectal anastomosis for slow transit constipation: long-term functional and quality of life results. *J Gastrointest Surg.* 2006; 10:1330–1336. discussion 1336–1337. [PubMed: 17175451]
167. You YT, Wang JY, Changchien CR, et al. Segmental colectomy in the management of colonic inertia. *Am Surg.* 1998; 64:775–777. [PubMed: 9697912]
168. Lundin E, Karlbom U, Pahlman L, et al. Outcome of segmental colonic resection for slow-transit constipation. *Br J Surg.* 2002; 89:1270–1274. [PubMed: 12296895]
169. Preston DM, Hawley PR, Lennard-Jones JE, et al. Results of colectomy for severe idiopathic constipation in women (Arbuthnot Lane's disease). *Br J Surg.* 1984; 71:547–552. [PubMed: 6733431]
170. de Graaf EJ, Gilberts EC, Schouten WR. Role of segmental colonic transit time studies to select patients with slow transit constipation for partial left-sided or subtotal colectomy. *Br J Surg.* 1996; 83:648–651. [PubMed: 8689210]
171. Sunderland GT, Poon FW, Lauder J, et al. Videoproctography in selecting patients with constipation for colectomy. *Dis Colon Rectum.* 1992; 35:235–237. [PubMed: 1740067]
172. Kamm MA, Hawley PR, Lennard-Jones JE. Outcome of colectomy for severe idiopathic constipation. *Gut.* 1988; 29:969–973. [PubMed: 3396968]
173. Kuijpers HC. Application of the colorectal laboratory in diagnosis and treatment of functional constipation. *Dis Colon Rectum.* 1990; 33:35–39. [PubMed: 2295275]
174. Young-Fadok T, Pemberton J, Camilleri M. A case-controlled study of laparoscopic abdominal colectomy and ileorectal anastomosis (TAC-IRA) for slow-transit constipation (STC) (abstr). *Gastroenterology.* 2001; 120:A476.
175. Hsiao K, Jao S, Wu C, et al. Hand-assisted laparoscopic total colectomy for slow transit constipation. *Int J Colorectal Dis.* 2008; 23:419–424. [PubMed: 18193433]
176. Pinedo G, Zarate AJ, Garcia E, et al. Laparoscopic total colectomy for colonic inertia: surgical and functional results. *Surg Endosc.* 2009; 23:62–65. [PubMed: 18401647]
177. Nyam D, Pemberton J, Camilleri M. Total colectomy with ileorectostomy (IRA) for constipation-predominant intestinal dysmotility. Outcome at 5 years (abstr). *Gastroenterology.* 1996; 110:A725.

178. Redmond JM, Smith GW, Barofsky I, et al. Physiological tests to predict long-term outcome of total abdominal colectomy for intractable constipation. *Am J Gastroenterol.* 1995; 90:748–753. [PubMed: 7733081]
179. O'Knowles C, Scott M, Lunniss P. Outcome of colectomy for slow transit constipation. *Ann Surg.* 1999; 230:627–638. [PubMed: 10561086]
180. Malone PS, Ransley PG, Kiely EM. Preliminary report: the antegrade continence enema. *Lancet.* 1990; 336:1217–1218. [PubMed: 1978072]
181. Williams NS, Hughes SF, Stuchfield B. Continent colonic conduit for rectal evacuation in severe constipation. *Lancet.* 1994; 343:1321–1324. [PubMed: 7910324]
182. Bani-Hani AH, Cain MP, Kaefer M, et al. The Malone antegrade continence enema: single institutional review. *J Urol.* 2008; 180:1106–1110. [PubMed: 18639902]
183. Wong S, Lubowski D. Slow-transit constipation: evaluation and treatment. *ANZ J Surg.* 2007; 77:320–328. [PubMed: 17497967]
184. Kamm MA, Dudding TC, Melenhorst J, et al. Sacral nerve stimulation for intractable constipation. *Gut.* 2010; 59:333–340. [PubMed: 20207638]
185. Holzer B, Rosen HR, Novi G, et al. Sacral nerve stimulation in patients with severe constipation. *Dis Colon Rectum.* 2008; 51:524–529. discussion 529–530. [PubMed: 18322757]
186. Maeda Y, Lundby L, Buntzen S, et al. Sacral nerve stimulation for constipation: suboptimal outcome and adverse events. *Dis Colon Rectum.* 2010; 53:995–999. [PubMed: 20551750]
187. Keighley MR, Shouler P. Outlet syndrome: is there a surgical option? *J R Soc Med.* 1984; 77:559–563. [PubMed: 6747979]
188. Kamm MA, Hawley PR, Lennard-Jones JE. Lateral division of the puborectalis muscle in the management of severe constipation. *Br J Surg.* 1988; 75:661–663. [PubMed: 3416122]
189. Maria G, Cadeddu F, Brandara F, et al. Experience with type A botulinum toxin for treatment of outlet-type constipation. *Am J Gastroenterol.* 2006; 101:2570–2575. [PubMed: 17029615]
190. Faried M, El Nakeeb A, Youssef M, et al. Comparative study between surgical and non-surgical treatment of anismus in patients with symptoms of obstructed defecation: a prospective randomized study. *J Gastrointest Surg.* 2010; 14:1235–1243. [PubMed: 20499203]
191. Ellerkmann RM, Cundiff GW, Melick CF, et al. Correlation of symptoms with location and severity of pelvic organ prolapse. *Am J Obstet Gynecol.* 2001; 185:1332–1337. discussion 1337–1338. [PubMed: 11744905]
192. Orrom WJ, Bartolo DC, Miller R, et al. Rectopexy is an ineffective treatment for obstructed defecation. *Dis Colon Rectum.* 1991; 34:41–46. [PubMed: 1991419]
193. Graf W, Karlhom U, Pahlman L, et al. Functional results after abdominal suture rectopexy for rectal prolapse or intussusception. *Eur J Surg.* 1996; 162:905–911. [PubMed: 8956961]
194. Farouk R, Bhardwaj R, Phillips RKS. Stapled transanal resection of the rectum (STARR) for the obstructed defaecation syndrome. *Ann R Coll Surg Engl.* 2009; 91:287–291. [PubMed: 19416586]
195. Lehur PA, Stuto A, Fantoli M, et al. ODS II Study Group. Outcomes of stapled transanal rectal resection vs. biofeedback for the treatment of outlet obstruction associated with rectal intussusception and rectocele: a multicenter, randomized, controlled trial. *Dis Colon Rectum.* 2008; 51:1611–1618. [PubMed: 18642046] [erratum appears in *Dis Colon Rectum* 2008;51:1739].
196. Reboa G, Gipponi M, Logorio M, et al. The impact of stapled transanal rectal resection on anorectal function in patients with obstructed defecation syndrome. *Dis Colon Rectum.* 2009; 52:1598–1604. [PubMed: 19690488]
197. Titu LV, Riyad K, Carter H, et al. Stapled transanal rectal resection for obstructed defecation: a cautionary tale. *Dis Colon Rectum.* 2009; 52:1716–1722. [PubMed: 19966603]
198. Gagliardi G, Pescatori M, Altomare DF, et al. Italian Society of Colo-Rectal Surgery (SICCR). Results, outcome predictors, and complications after stapled transanal rectal resection for obstructed defecation. *Dis Colon Rectum.* 2008; 51:186–195. discussion 195. [PubMed: 18157718]

199. Schwandner T, Hecker A, Hirschburger M, et al. Does the STARR procedure change the pelvic floor: a preoperative and postoperative study with dynamic pelvic floor MRI. *Dis Colon Rectum*. 2011; 54:412–417. [PubMed: 21383560]
200. Dodi G, Pietroletti R, Milito G, et al. Bleeding, incontinence, pain and constipation after STARR transanal double stapling rectotomy for obstructed defecation. *Tech Coloproctol*. 2003; 7:148–153. [PubMed: 14628157]
201. Corman ML, Carriero A, Hager T, et al. Consensus conference on the stapled transanal rectal resection (STARR) for disordered defaecation. *Colorectal Dis*. 2006; 8:98–101. [PubMed: 16412068]
202. Madbouly KM, Abbas KS, Hussein AM. Disappointing long-term outcomes after stapled transanal rectal resection for obstructed defecation. *World J Surg*. 2010; 34:2191–2196. [PubMed: 20533038]
203. Jorge JM, Yang YK, Wexner SD. Incidence and clinical significance of sigmoidoceles as determined by a new classification system. *Dis Colon Rectum*. 1994; 37:1112–1117. [PubMed: 7956579]
204. Maher C, Feiner B, Baessler K, et al. Surgical management of pelvic organ prolapse in women. *Cochrane Database Syst Rev*. 2010; 4:CD004014. [PubMed: 20393938]
205. Barbara, L.; Corinaldesi, R.; Gizza, G., et al. *Chronic constipation*. W. B. Saunders Co; 1996.
206. Talley NJ, Jones M, Nuyts G, et al. Risk factors for chronic constipation based on a general practice sample. *Am J Gastroenterol*. 2003; 98:1107–1111. [PubMed: 12809835]
207. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized, placebo-controlled studies. *Aliment Pharmacol Ther*. 2009; 29:329–341. [PubMed: 19006537]
208. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. *N Engl J Med*. 2011; 365:527–536. [PubMed: 21830967]
209. Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. *Gastroenterology*. 2010; 139:1877–1886.e2. [PubMed: 20801122]
210. Bleijenberg G, Kuijpers HC. Biofeedback treatment of constipation: a comparison of two methods. *Am J Gastroenterol*. 1994; 89:1021–1026. [PubMed: 8017359]
211. Koutsomanis D, Lennard-Jones JE, Roy AJ, et al. Controlled randomised trial of visual biofeedback versus muscle training without a visual display for intractable constipation. *Gut*. 1995; 37:95–99. [PubMed: 7672690]
212. Heymen S, Wexner SD, Vickers D, et al. Prospective, randomized trial comparing four biofeedback techniques for patients with constipation. *Dis Colon Rectum*. 1999; 42:1388–1393. [PubMed: 10566525]
213. Glia A, Gylin M, Gullberg K, et al. Biofeedback retraining in patients with functional constipation and paradoxical puborectalis contraction: comparison of anal manometry and sphincter electromyography for feedback. *Dis Colon Rectum*. 1997; 40:889–895. [PubMed: 9269803]
214. Farid M, El Monem HA, Omar W, et al. Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients. *Int J Colorect Dis*. 2009; 24:115–120.
215. Simon MA, Bueno AM. Behavioural treatment of the dyssynergic defecation in chronically constipated elderly patients: a randomized controlled trial. *Appl Psychophysiol Biofeedback*. 2009; 34:273–277. [PubMed: 19618262]

Table 1

Definitions of Constipation

Rome III criteria		Criteria used in pharmacologic studies	
Constipation ^a	IBS-C ^a	Constipation ^b	IBS-C ^c
Symptoms for 6 months and 2 of the following symptoms for more than one-fourth of defecations during the past 3 months: <ul style="list-style-type: none"> • Straining • Lumpy or hard stools • Sensation of incomplete evacuation • Sensation of anorectal obstruction/blockade • Manual maneuvers to facilitate defecations; <3 defecations/wk • Loose stools are not present, and there are insufficient criteria for IBS 	Recurrent abdominal pain or discomfort at least 3 days per month in the past 3 months associated with 2 or more of the following: <ul style="list-style-type: none"> • Improvement with defecation • Onset associated with change in frequency of stool • Onset associated with change in form (appearance) of stool • <25% of bowel movements were loose stools 	<3 SBMs per week and 1 of the following symptoms for at least 12 weeks during the preceding 12 months: <ul style="list-style-type: none"> • Straining in more than one-fourth of defecations • Lumpy or hard stools in more than one-fourth of defecations • Sensation of incomplete evacuation in more than one-fourth of defecations • No loose or watery SBMs (Bristol Stool Form Scale score of 6&dash;7) 	<3 SBMs per week and 1 of the following symptoms for at least 12 weeks during the preceding 12 months: <ul style="list-style-type: none"> • Straining in one-fourth or more of defecations • Lumpy or hard stools in one-fourth or more of defecations • Sensation of incomplete evacuation in one-fourth or more of defecations • Mean score of 2.0 for daily nonmenstrual abdominal pain or discomfort (5-point scale ranging from 1 = none to 5 = very severe) • Mean of <3 complete SBMs and 6 SMBs per week

SBM, spontaneous bowel movements.

^aModified from Longstreth et al.⁷

^bModified with permission from Lembo et al.¹⁴⁸

^cModified with permission from Johnston et al.¹⁴⁹

Table 2

Medications Associated With Constipation

Class	Examples
5-HT ₃ receptor antagonists	Ondansetron
Analgesics	
Opiates ^a	Morphine
Nonsteroidal anti-inflammatory agents ^b	Ibuprofen
Anticholinergic agents	Librax, belladonna
Tricyclic antidepressants ^a	Amitriptyline > nortriptyline
Antiparkinsonian drugs	Benzotropine
Antipsychotics	Chlorpromazine
Antispasmodics ^a	Dicyclomine
Antihistamines ^a	Diphenhydramine
Anticonvulsants ^a	Carbamazepine
Antihypertensives	
Calcium channel blockers	Verapamil, nifedipine
Diuretics ^{a,c}	Furosemide
Centrally acting	Clonidine
Antiarrhythmics	Amiodarone
Beta-adrenoceptor antagonist	Atenolol
Bile acid sequestrants	Cholestyramine, colestipol
Cation-containing agents	
Aluminum ^a	Antacids, sucralfate
Calcium	Antacids, supplements
Bismuth	
Iron supplements	Ferrous sulfate
Lithium	
Chemotherapy agents	
Vinca alkaloids	Vincristine
Alkylating agents	Cyclophosphamide
Miscellaneous compounds	Barium sulfate, oral contraceptives, polystyrene resins
Endocrine medications	Pamidronate and alendronic acid
Other antidepressants	Monoamine oxidase inhibitors
Other antipsychotics	Clozapine, haloperidol, risperidone
Other antiparkinsonian drugs	Dopamine agonists
Other antispasmodics	Mebeverine, peppermint oil
Sympathomimetics	Ephedrine, terbutaline

5-HT, 5-hydroxytryptamine.

Adapted with permission from Branch RL, Butt TF. Drug-induced constipation. *Adv Drug Reaction Bull* 2009;257:987–990.

^aDrugs associated with constipation in community-based studies.^{23,206}

^cPerhaps related to electrolyte disturbances.

\$watermark-text

\$watermark-text

\$watermark-text

Table 3**Common Medical Conditions Associated With Constipation**

Drug effects
See Table 2
Mechanical obstruction
Colon cancer
External compression from malignant lesion
Strictures: diverticular or posts ischemic
Rectocele (if large)
Postsurgical abnormalities
Megacolon
Anal fissure
Metabolic conditions
Diabetes mellitus
Hypothyroidism
Hypercalcemia
Hypokalemia
Hypomagnesemia
Uremia
Heavy metal poisoning
Myopathies
Amyloidosis
Scleroderma
Neuropathies
Parkinson's disease
Spinal cord injury or tumor
Cerebrovascular disease
Multiple sclerosis
Other conditions
Depression
Degenerative joint disease
Autonomic neuropathy
Cognitive impairment
Immobility
Cardiac disease

Adapted from *Gastroenterology*, Vol. 119, Locke GR, Pemberton JH, and Phillips SF, AGA technical review on constipation, 1766-1778, copyright 2000, with permission from the American Gastroenterological Association.

Table 4

Summary of Medications Commonly Used for Constipation

Type	Generic name	Trade name	Dosage	Side effects	Time to onset of action (h)	Mechanism of action
Fiber	Bran	—	1 cup/day	Bloating, flatulence, iron and calcium malabsorption	—	Stool bulk increases, colonic transit time decreases, gastrointestinal motility increases
	Psyllium	Metamucil Perdiem with fiber	1 tsp up to 3 times daily	Bloating, flatulence	—	
	Methylcellulose	Citrucel	1 tsp up to 3 times daily	Less bloating	—	
	Calcium polycarbophil	FiberCon	2—4 tablets once daily	Bloating, flatulence	—	
Stool softener	Docusate sodium	Colace	100 mg twice daily		12—72	
	Sorbitol	—	15—30 mL once daily or twice daily	Sweet tasting, transient abdominal cramps, flatulence	24—48	Nonabsorbable disaccharides metabolized by colonic bacteria into acetic acid and other short-chain fatty acids
Hyperosmolar agents	Lactulose	Chronulac	15—30 mL once daily or twice daily	Same as sorbitol	24—48	
	PEG	Golytely Colyte Miralax	8—32 oz once daily	Incontinence due to potency	0.5—1	Osmotically increases intraluminal fluids
	Glycerin		Suppository; up to daily	Rectal irritation	0.25—1	Evacuation induced by local rectal stimulation
	Bisacodyl	Dulcolax	10-mg suppositories or xx by mouth up to 3 times/wk	Incontinence, hyperkalemia, abdominal cramps, rectal burning with daily use of suppository form	0.25—1	Bisacodyl and sodium picosulfate are prodrugs that are hydrolyzed by colonic bacteria (sodium picosulfate) or intestinal and colonic brush border enzymes (bisacodyl) to the active metabolite (bis-(p-hydroxyphenyl)-pyridyl-2-methane, which has anti-absorptive/secretory and prokinetic effects
Stimulant	Picosulfate					Similar to bisacodyl
	Antraquinones (senna, cascara)	Senokot Perdiem (plain) Peri-Colace	2 tablets once daily to 4 tablets twice daily 1—2 tsp once daily 102 tablets once daily	Degeneration of Meissner's and Auerbach's plexus (unproven), malabsorption, abdominal cramps, dehydration, melanosis coli	8—12 8—12 8—12	Electrolyte transport altered by increased intraluminal fluids; myenteric plexus stimulated; motility increases

Type	Generic name	Trade name	Dosage	Side effects	Time to onset of action (h)	Mechanism of action
Saline laxative	Magnesium	Milk of magnesia Hailey's MO (with mineral oil)	15–30 mL once daily or twice daily 15–30 mL once daily or twice daily	Magnesium toxicity, dehydration, abdominal cramps, incontinence	1–3 1–3	Fluid osmotically drawn into small bowel lumen; cholecystokinin stimulated; colon transit time decreases
Lubricant	Mineral oil	–	15–45 mL	Lipid pneumonia, malabsorption of fat-soluble vitamins, dehydration, incontinence	6–8	Stool lubricated
Enemas	Mineral oil retention enema Tap water enema Phosphate enema Soapsuds enema	– – Fleet –	199–25 0mL once daily per rectum 500 mL per rectum 1 unit per rectum 1500 mL per rectum	Incontinence, mechanical trauma Mechanical trauma Accumulated damage to rectal mucosa, hyperphosphatemia, mechanical trauma Accumulated damage to rectal mucosa, mechanical trauma	6–8 5–15 min 5–15 min 2–15 min	Stool softened and lubricated Evacuation induced by distended colon; mechanical lavage

Adapted from Gastroenterology, Vol. 119, Locke GR, Pemberton JH, and Phillips SF, AGA technical review on constipation, 1766-1778, copyright 2000, with permission from the American Gastroenterological Association.

Table 5

Newer Pharmacologic Approaches for Constipation

Generic name (chemistry)	Mechanism of action	Metabolism, bioavailability	Pharmacodynamic effects	Clinical trials	Common side effects	Cardiovascular safety ^a
Secretagogues						
Lubiprostone (prostone) ^b	Stimulate intestinal chloride and fluid secretion by activating chloride channels	Intestinal degradation, minimal oral bioavailability	Accelerated small bowel and colonic transit in health	Phase 2 and 3 in CC, IBS-C	Diarrhea, nausea	No arrhythmic effects
Linaclotide	Stimulate intestinal chloride and fluid secretion by activating CFTR	Intestinal degradation, minimal oral bioavailability	Dose-related acceleration of colonic transit in IBS-C	Phase 2 and 3 in CC, IBS-C	Diarrhea	No arrhythmic effects
Serotonin 5-HT ₄ receptor agonists						
Prucalopride ^c (benzofuran carboxamide)	High selectivity and affinity for 5-HT ₄ receptors; much weaker affinity for human D4 and s1 and mouse 5-HT ₃ receptors	Limited hepatic, not CYP3A4	Accelerated colonic transit in health and CC	Phase 2 and 3 in CC	Diarrhea, headache	No arrhythmic activity in atrial cells; inhibits hERG at very high μmol/L concentration; no clinically relevant adverse cardiac effects in large trials (>4000 subjects)

NOTE: Only agents that have been tested in phase 3 clinical trials are included.

CC, chronic constipation.

^aIn addition to the listed effects, none of the agents shown in this table affect QTc in healthy subjects.

^bApproved by the FDA.

^cApproved by the European Agency for Evaluation of Medicinal Products.

Table 6

Comparison of Efficacy of Approved, Over-the-Counter, and Phase 3 Completed but not Approved Pharmacologic Therapies for Relief of Chronic Constipation and IBS-C

Agent	Chronic constipation			IBS-C		
	Number needed to treat	Number of patients	Quality of evidence	Number needed to treat	Number of patients	Quality of evidence
Soluble fiber	^a	368 ¹¹¹	Very low	4,5 ¹¹⁴	275	Moderate
Osmotic and stimulant laxatives	3 (2–4)	1411	High	NA	NA	Moderate ^b
PEG	2,4 ¹¹⁷	573	High	NA	NA	Moderate ^b
Lubiprostone	4 (3–7)	610	Moderate	13 ²⁰⁷	1171	Moderate
Linaclootide	6 (5–8)	2858 ²⁰⁸	Moderate	10 ²⁰⁹	420	Moderate
Prucalopride	6 (5–9)	2639	Moderate	NA	NA	Very low

NOTE. Numbers in parentheses reflect 95% confidence intervals where available. Except where cited otherwise, data for therapeutic efficacy and numbers of patients with chronic idiopathic constipation are obtained from a meta-analysis of several trials.²

NA, not available.

^a Although some trials suggest that dietary fiber is effective in patients with chronic constipation, the efficacy cannot be estimated reliably because the quality of the evidence is very low.

^b Although no controlled clinical trials have been conducted in patients with IBS-C, indirect evidence from trials in chronic constipation, the mechanism of action of these agents, and clinical experience suggest they are also likely to be effective in patients with IBS-C.

Table 7

Controlled Trials of Behavioral Treatment for Defecatory Disorders in Adults

Reference	Patients (n)	Behavioral treatment	Design and comparator	Main results
Bleijenberg and Kuijpers, 1994 ²¹⁰	DD (20)	Intra-anal EMG BF	RCT vs balloon training	Symptoms improved: BF (73%) vs balloon (22%)
Koutsomanis et al, 1995 ²¹¹	Constipation (60); DD (47)	EMG and rectal balloon BF	RCT vs muscular coordination training + balloon	Symptoms improved to a similar extent in both arms
Heymen et al, 1999 ²¹²	Constipation (36)	4 anal EMG BF arms	RCT	Relative to baseline, EMG BF alone was as effective as EMG + balloon training, home training, or both
Glia et al, 1997 ²¹³	DD (20)	Perianal EMG BF	RCT vs pressure BF + balloon training	Symptoms improved to a similar extent in both arms
Chiarioni et al, 2005 ⁵⁷	STC (52); DD (32), mixed (6), STC alone (12)	Anal EMG and balloon BF to teach relaxation	Open trial + abdominal muscle training to teach straining	At 6 months, symptom response (< 3 bowel movements/wk) in 71% of the group with puborectalis dyssynergia vs 8% of the group with STC; improvements were maintained at 24 months of follow-up; improved defecation dynamics
Chiarioni et al, 2006 ¹⁶³	DD (99)	BF	RCT vs PEG (14.6–29.2 g/day) + counseling	At 6 months, major clinical improvement in 80% of the BF group versus 20% of the PEG group; results sustained for 2 y
Rao et al, 2007 ¹⁶⁴	DD (77)	BF	RCT vs sham (relaxation prescription)	88% (BF) satisfactory response vs 48% on control; improved defecation dynamics
Heymen et al, 2007 ¹⁶⁵	DD (84)	EMG BF + pelvic floor exercises	3-arm RCT vs diazepam or placebo 1–2 h before attempt to defecate	Adequate relief of constipation: 70% (BF) vs 23% (diazepam) vs 38% (placebo); more unassisted bowel movements and reduced strain
Farid et al, 2009 ²¹⁴	DD (48)	Balloon pressure BF	RCT; botulinum toxin A to external anal sphincter	1-month improvement: BF vs botulinum toxin A 71% ($P = .008$); 1-year improvement: 25% vs 33%
Simon and Bueno, 2009 ²¹⁵	Elderly DD (30)	EMG BF	Counseling on behavioral mechanisms in defecation	Improved symptoms and EMG results in the biofeedback group at 4 wk and 2 mo

DD, defecatory disorders; EMG, electromyography; BF, biofeedback; RCT, randomized controlled trial.

Adapted from Gut, Camilleri M and Bharucha AE, Behavioral and new pharmacological treatments for constipation: getting the balance right, Vol. 59, 1288-96, copyright 2010, with permission from BMJ Publishing Group Ltd.³